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ABSTRACT 
Immunological Effects of Amphotericin B Desoxycholate 
and Liposomal Amphotericin B on Splenocytes from 
Immune-Normal and Immune-Compromised Mice 




Jay Jenson Schindler 
Utah State University, 1992 
Dr . Stanley D. Allen 
Animal, Dairy and Veterinary Science 
Antifungal Agents 
xvii 
Because of the increasing number of serious risk factors which 
predispose a normally immune competent host to infection, the incidence 
of systemic fungal infections is steadily increasing . This epidemiological 
rise has especially become apparent since the onset of the AIDS epidemic. 
Amphotericin 8 is the drug of choice for these life-threatening mycotic 
infections. Complications due to drug toxicity, however, severely limit 
amphotericin B's clinical usefulness . The major complication associated 
with the administration of amphotericin 8 is renal toxicity. Research has 
indicated, however, that besides its antifungal activities, amphotericin 8 
may act as an immune stimulant of both humoral and cellular responses . 
xviii 
A new formulation, liposomal amphotericin B, has been developed 
which has proven to be significantly less toxic to the kidneys. Research 
has suggested that liposomal amphotericin B may also act as an immune 
stimulant. Recent reports have also suggested that its stimulatory 
capabilities may possibly exceed those of the non-liposomal preparations. 
The purpose of this study was to quantify the specific effects of 
amphotericin B and liposomal amphotericin B on the in vitro indices: 
cellular viability, B- and T-lymphocyte proliferation and macrophage 
activation as indicators of immune system functions . Spleen cells from 
immune normal, and immune compromised BALB/c female mice were 
harvested following euthanasia and incubated in the presence of the two 
drugs. Drug doses were chosen to correlate with those surrounding 
clinically relevant plasma concentrations . Cyclosporine and 
cyclophosphamide were used as immune suppressants to simulate organ 
transplant patients and patients receiving cancer chemotherapy, 
respectively. 
Results indicated that amphotericin B consistently reduces the ability 
of B-cells and T-cells to proliferate and the ability of macrophages to 
produce interleukin-1. Though direct cytotoxicity may play a part in these 
assays, it is probably minor because viability studies show no more than a 
ten percent reduction due to amphotericin B compared with its liposomal 
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analogue. 
Liposomal amphotericin B was shown to be non-toxic in each of the 
immune parameters . It appeared that liposomes may be an important 
means of delivering more drug to a host infected with a fungal organism 




Statement of the Problem. Fungal infections are generally no threat 
to the normal, healthy population. They have become a major source of 
both morbidity and mortality in the immune compromised host, however, 
manifesting themselves as secondary, opportunistic infections due to the 
inability of a host's immune system to successfully prevent or contain 
colonization . 
Because fungal infections occur as opportunists in already immune-
compromised patients, it is imperative that antifungal therapy doesn ' t 
further impede an immune system's defense mechanisms. Contrary to 
attitudes and beliefs which arose secondary to the euphoria which existed 
for decades following the antibiotic boom of the mid-20th century, it is 
now understood that the most important factor in controlling and 
eliminating infections is not antibiotic therapy but the patient's own 
immune system. 
Much work has recently been undertaken to discover and develop 
compounds which can augment the immune system. The clinical 
implications that such compounds could have in both immune normal and 
especially in immune compromised patients is only imaginable . If a 
particular antibiotic was not only toxic to an infectious organism but would 
concurrently stimulate the patient's immune system to mount a stronger 
response, a new era of medicine would certainly evolve. Such have been 
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the implications associated with the use of amphotericin B desoxycholate 
which is the drug of choice for most life-threatening fungal infections. 
Blanke et al . reported as early as 1977 that amphotericin B was able to 
augment both humoral as well as cell-mediated immunity ( 12) . Lopez-
Berestein et al. supported this possibility in 1983 by reporting that 
amphotericin B stimulated B-lymphocytes, T-lymphocytes and macrophages 
(46) . By 1986, reports were being published which indicated that 
amphotericin B's ability to stimulate the immune system might even have 
important prophylactic implications against fungal infections (69) . Reports 
which entirely contradict these observations have also been reported. In 
1985, Mehta et al. reported that amphotericin B suppressed both humoral 
and cell mediated immunity as well as the activity of macrophages (49). 
The major concern with the use of amphotericin B has been its 
severe renal toxicity . Because of this complication, new formulations have 
been developed in attempts to maintain its antifungal potency while 
eliminating its toxic effects . Liposomal amphotericin B has been one of the 
most promising of these formulations. Besides reducing renal toxicity, this 
preparation has been reported to also be an immune-stimulant (45, 46, 48). 
Obviously, the effects of amphotericin Bon the immune system are 
controversial. The effects on the immune system of liposomal amphotericin 
B have not been studied as extensively as that of the desoxycholate form 
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of the drug . Finally, the relationship between amphotericin B desoxycholate 
and liposomal amphotericin B and their effects on the immune systems of 
both immune normal and immune compromised hosts have not been 
elucidated. 
Objectives. The objectives of this study are to quantify the effects 
which amphotericin B (Fungizone) and liposomal amphotericin B AmBisome) 
have on the immune systems of various in vitro immune-normal and 
immune-compromised models . Drug effects on cellular viability, B-andT-
lymphocyte proliferation and macrophage activation as determined by their 
production of interleukin-1 will be determined on murine splenocytes. In 
order to relate these effects to the clinical setting where opportunistic 
fungal infections cause their problems, immune cells from mice 
immunosuppressed with cyclosporine and cyclophosphamide will also be 
studied in addition to immune normal models . 
Experimental Design. Figure 1 illustrates the experimental design 
utilized for each of the different studies, i.e., splenocyte viability, B-
lymphocyte proliferation, T-lymphocyte proliferation and macrophage 
activation . Production of interleukin-1 was the index used to determine 
activation of macrophages and was quantified by the stimulation of 
thymocytes exposed to the interleukin-1 . The two exceptions to this 









FIGURE 1. Experimental design for testing amphotericin B (Fungizone) and 
liposomal amphotericin B (AmBisome) with each assay i.e., viability studies, 
B-lymphocyte and T-lymphocyte proliferation studies and macrophage 
activation studies with the exceptions that neither of the drugs was tested 
at 0.5 pg/ml in the macrophage activation studies and viability was only 
tested on splenocytes from immune normal mice . 
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tested at 0 .5 pg /ml in the macrophage activation studies . Also, viability 
was only tested on splenocytes from immune normal mice. 
Limitations of the Study. The main limitation associated with this 
study is the fact that all conclusions are based on in vitro testing . Though 
this is a reliable initial approach, results will need to be confirmed in vivo. 
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REVIEW OF LITERATURE 
For many years, medical mycology remained a field that was little 
researched and somewhat obscure. This was mainly because there were 
such a variety of other, more harmful diseases, such as those of bacterial 
or viral origin, that fungal diseases did not demand a great deal of attention . 
In the 1984 publication of A Clinician's Guide to Fungal Diseases, Roberts 
et al. stated that even at that time, the study of mycology was one 
surrounded by "considerable ignorance and confusion" and that its study 
received "scant attention" (p . iii) . They also stated that the new medical 
graduate was ill -equipped to cope with the situation at large (57) . 
Although a few good antibiotics exist for fungal infections, their 
usefulness is often severely limited due to complications associated with 
drug toxicity . Amphotericin B desoxycholate, the drug of choice for 
systemic fungal infections, is severely limited due to its toxicity, particularly 
to the kidneys. This is especially unfortunate because amphotericin B has 
been reported to actually enhance normal immune responses (12, 46, 49, 
69) . 
A new formulation of the drug, liposomal amphotericin B, in which 
amphotericin B has been incorporated into lipid vesicles, has been reported 
to have the same antifungal properties as the desoxycholate form of the 
drug but with significantly reduced toxicity. It has also been reported to 
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stimulate the immune system even more than amphotericin B 
desoxycholate (45, 46, 48) . 
Fungal Infections. The pathological conditions caused by fungal 
infections can be classified according to their location as well as by the 
organism itself. Fungal infections can be grouped into four basic 
categories . The first type of infection is superficial such as ringworm or 
athletes foot , in which the cornified layer of the skin is affected . The 
second type of infection remains relatively superficial but is found localized 
on mucous membranes such as the mouth or genitalia . Examples of these 
types include oral thrush and candida! vaginitis. The third type of mycotic 
infection is found deeper within the bony or subcutaneous tissues; 
however, these infections remain localized, usually to a specific organ such 
as the lungs as is the case with pulmonary blastomycosis . The fourth are 
those which are systemic throughout the body tissues. Examples of these 
are disseminated candidiasis or cryptococcoses . Fungal diseases are also 
associated with allergies, direct poisoning , food spoilage and crop failure 
(57) . 
Normal immunological responses to fungal infections. Probably the 
largest single reason why mycoses had evaded the concentrated efforts of 
medical researchers for so long was attributable to the normally high quality 
of man's innate immunity in developed nations. In third world countries 
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where fungal infections have always been prevalent, the financial 
opportunities did not exist to persuade pharmaceutical companies to 
conduct expensive research and produce costly remedies for which they 
could not profit . It has also only been fairly recently that medical 
interventions such as organ transplants, cancer chemotherapies and AIDS 
have resulted in significant numbers of immune-compromised individuals . 
Because of excellent defense mechanisms, the immune-normal host 
is resistant to most fungal pathogens. Normal defense mechanisms to 
fungal infections are both nonspecific as well as specific . Intact skin, 
which is generally desiccated and has a high epithelial turnover, is the first 
line of nonspecific defense involved in host protection. The washing action 
of tears as well as saliva and urine generally keeps unwanted pathogens 
from colonizing the body . The pH of the vagina, sebum from the 
sebaceous glands and even blood serum inhibit fungal growth as well (57). 
Normal body flora also keeps unwanted organisms at bay through microbial 
antagonism. A good example of this is the acid pH of the vagina . The 
Lactobacilli sp. , which normally inhabit the vaginal canal, produce acidic 
byproducts from the metabolism of glycogen which, in turn, keep fungi 
such as Candida albicans under control. 
In general, non-specific cellular immunity has been demonstrated to 
be relatively nonspecific to the specific insulting organism following the 
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establishment of an infection (65) . Phagocytosis is one of the most 
important non-specific factors in clearing an organism's blood of fungal 
pathogens . Following the infection of a tissue, a fungal infection is first 
met by an inflammatory response involving neutrophils . Tissue 
macrophages and circulating monocytes also play a significant role in 
phagocytosis (57) . This has been demonstrated both in vitro and in vivo 
(69). Whether or not the monocytes or the neutrophils are more important 
seems to be dependent upon the type of infection as well as t he stage of 
disease . For instance, in experimental aspergillosis, the neutrophils are 
most active against the filamentous phase whereas the macrophages seem 
to be of more importance against the spores . The action of monocytes is 
often antibody dependent demonstrating the close, opsonizing 
interrelationship between various parts of the immune defenses (57) . Katz 
et al. demonstrated in 1991 that the specific type of tissue macrophage is 
also of importance . They noted that alveolar macrophages in the lungs 
were much more active than liver Kupffer cells in their abil ity to trap 
Candida albicans injected via the tail vein in rats (38) . 
Research has also established the importance of both humoral and 
cell-mediated lines of defence as specific factors important in resistance to 
mycotic infections (46). 8- and T-lymphocyte functions are the body's 
response to the wide array of antigens presented by the offending 
10 
eukaryotic fungal organisms. Though antibodies were long thought to be 
of little importance, their production has since been shown to be important 
in the course of an infection. Though it seems apparent that antibodies do 
not play as dominant a role in fungal infections as they do in non-fungal, 
extracellular infections, their assistance to the other immune parameters 
has been shown to be critical. One example of this is the killing of 
Cryptococcus neoformans by mononuclear cells. Monocytes are able to kill 
the fungal cells through an extracellular mechanism much more easily when 
the pathogen is coated with antibodies. This is the process of opsonization 
which helps monocytes and macrophages both recognize and phagocytize 
pathogens more easily (57). 
T-cell mediated functions, however, are generally considered to be 
the more important mechanism against fungal infections (39, 46, 57). This 
has been determined from both clinical and experimental observations. 
Patients and animals with severely depressed cell-mediated immunity are 
extremely susceptible to fungal colonization. Rather than direct cell killing, 
the mechanism of defense is believed to occur mainly through the 
production of lymphokines. This is another form of interaction between 
different immune parameters in which macrophages are stimulated by 
lymphokines to phagocytize the offending fungal cells. In all cases of deep 
mycoses such as coccidioidomycosis, histoplasmosis, blastomycosis and 
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some types of candidiasis, the suppressed cell mediated activity was 
demonstrable by "negative skin tests to extracts of the infecting fungus, 
or by failure in vitro of lymphocytes to undergo blast transformation, or of 
macrophages to migrate in the presence of fungal antigen" (57, p. 35) . 
This would indicate the host's inability to produce the lymphokines which 
normally would induce lymphocyte transformation and the migration of 
macrophages to the offending antigen . This demonstrates the intimate 
interactions which occur between both the non-specific and specific 
segments of the immune response . 
The advent of an infection is usually considered in light of either a 
high dose inoculum of the pathogenic organism or general host 
susceptibility (57) . Because an immune-normal host is generally capable of 
resisting opportunistic fungi which are ubiquitous in the environment, a 
fungal infection is generally manifest as a mild, self-limiting infection and 
is indicative of an abnormally high amount of pathogen taken in. Severe 
fungal infections are a sign that the high level of normal immune defenses 
has been compromised (57) . 
The immune -compromised host. Once again, it should be stressed 
that the defense mechanisms of an immune-normal host are generally 
adequate to withstand mycotic challenge. This is one of the major reasons 
why the field of mycology remained relatively undeveloped for so many 
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years. The field is rapidly changing, however, due to the ever growing 
number of patient risk factors which predispose a host to fungal infection . 
These immune-compromising conditions can generally be classified under 
two categories . 
The first category of immunosuppression results from iatrogenic 
factors that a patient may experience secondary to other medical 
intervention; therefore , allowing fungal species to fulminate . These are 
normal body commensals to become opportunists due to 
immunosuppression. Long-term antibiotic therapy, for example, can upset 
the normal microbiota within a body system and will predispose their 
tissues to a variety of fungal opportunistic infections . Such can be the 
case when the Lactobacilli sp. of the vagina are killed, allowing Candida 
albicans to fulminate because of the subsequent increase in pH . Other 
iatrogenic factors include different types of cancer chemotherapy, including 
both radiation and chemicals which Inhibit rapidly dividing cells . 
Cyclophosphamide is one of the most widely used anticancer drugs for this 
purpose. Other conditions, such as organ transplantation and bone marrow 
transplantation, open the door to mycotic complications as well (51). This 
is because normal immune responses must be directly suppressed with 
drugs such as cyclosporine so that the patient's defense mechanisms will 
not recognize the transplant as an offending antigen and thus reject it. 
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Corticosteroid therapy also predisposes a patient to fungal opportunists by 
inhibiting t he production of interleukin-1 by macrophages as well as the 
proliferation and differentiation of both humoral and cell mediated 
immunity . Fungal infections will also arise due to complications following 
surgical intervention or other procedures which may involve an indwelling 
catheter, such as hyperalimentation, or IV infusions (51) . 
The second category of immune-compromising situations occurs as 
a result of underlying pathological conditions. Burn patients are highly 
susceptible to fungal infections because their epithelial covering has been 
destroyed . Diabetics are also very familiar with fungal complications 
because of the abnormalities in their body sugar levels. One of the main 
reasons, however, why medical mycology has witnessed such an increased 
interest has been due to the epidemic caused by the human 
immunodeficiency virus (HIV). AIDS has essentially forced the once 
generally harmless mycogens to the forefront of medical research. In the 
immune-compromised condition of the AIDS patient, normal body defenses 
are rendered useless and pathogens such as Candida, Aspergillus and 
Cryptococcus become major causes of morbidity and high mortality. An 
overview of patient risk factors indicates the extent of damage which 
mycoses are now causing. Considering only oropharyngeal candidiasis as 
an example, one can see the problems associated with fungal infection in 
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various immune compromised patient groups. For instance, 30% of all 
solid tumor patients succumb to oropharyngeal candidiasis . Citing 
lymphoma patients as a specific example of this patient particular 
population , 13% of the patients who did succumb to fungal infections died 
and 80% of these infections were a result of oropharyngeal candidiasis 
(51) . 
Another high risk group for the procurement of potentially fatal 
fungal infections is leukemic patients . This is evident from the fact that 
one in five leukemic patients die from fungal infections . Specifically, 
leukemic patients have a 50% chance of succumbing to oropharyngeal 
candidiasis . This disease alone accounts for 80% of the mortality resulting 
from the total spectrum of mycotic infections in this particular patient risk 
group (51) . 
As previously noted, immunosuppressive therapy used in conjunction 
with organ transplantation is another high risk group. In a 1990 review of 
2121 cases previously reported in scientific literature, Demming and 
Stevens noted that "mortality from pulmonary aspergillosis in bone marrow 
transplant recipients exceeds 94% regardless of therapy, as does that from 
cerebral aspergillosis in all hosts" (23, p. 1147). This represents the 
overwhelming problem that a fungal infection can cause in an immune 
compromised host. 
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AIDS patients represent a risk group which has a much higher 
probability of procuring this type of opportunistic infection. An estimated 
95% of all AIDS patients are at high risk for the contraction of 
oropharyngeal candidiasis (51). In fact, fungal infections are the cause of 
the greatest morbidity and mortality in patients who are suffering from 
congenital or acquired deficiencies of their immune systems (46) . 
Immune-Compromising Agents. Though good models do not exist 
for every immune-compromising situation, some can be mimicked in 
research animal models by using the same drug formulations as are used 
in the therapy for conditions such as organ transplantation and cancer 
chemotherapy. Because they suppress the immune system, these agents 
generally increase the host's susceptibility to opportunistic infectious 
agents and to other anomalies such as various types of cancer, particularly 
of white blood cells (6) . 
As previously described, macrophages, monocytes and related 
phagocytic cells play a crucial part in the host's immune response against 
fungal infection . The salient features of this reaction are presented in 
Figure 2 . When an antigen such as a fungal opportunist is phagocytized by 
a macrophage, it is processed by the phagocyte which then performs two 
very important functions . The macrophage presents the processed antigen 





FIGURE 2. Mechanism by which antigenic fungal cells are attacked by 
various aspects of the immune system. Note especially the pivotal role 
played by macrophage activated T-helper cells in producing interleukins 
which activate both the cell-mediated as well as the humoral arms of the 
immune system. Also included is where the two immunosuppressants, 
cyclosporine and cyclophosphamide , block specific portions of the immune 
response . Adapted from Goodman and Gilman (27) . 
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histocompatibility (MHC) antigens . The macrophage also produces and 
secretes interleukin-1 (IL-1 ). T-helper cells are activated when they detect 
both an antigen in association with the proper MHC proteins. lnterleukin-1, 
also known as the endogenous pyrogen or lymphocyte activating factor, 
also stimulates T-helper cells. Upon such stimulation, the T-helper cells 
elaborate and secrete other interleukins . Two notable examples are 
interleukin-2 (IL-2) and interleukins-3, 4, and 5 (IL-3, 11-4 and 11-5). 
lnterleukin-2, also known as T-cell growth factor, stimulates the 
proliferation and differentiation of T-cells which have been antigenically 
stimulated and as a consequence of this stimulation, bear specific IL-2 
receptors. When cytotoxic T-cells are stimulated by IL-2, they proliferate 
and differentiate into both effector, cytotoxic T-cells (T, cells) and memory 
cytotoxic T-cells . Effector cytotoxic T-cells kill antigenic cells by direct 
killing as well as by the production of toxic peptides such as tumor necrosis 
factor (TNF). lymphotoxins and interferon. Memory cells make it possible 
for the immune system to mount both a faster and stronger secondary 
response (27). 
As mentioned above, T-helper cells also secrete interleukinS-3, 4 and 
5. These function primarily to stimulate antigen specific B-cells to 
proliferate and differentiate into plasma cells and B-memory cells and may 
play a role in the lgG to lgM switch. Plasma cells secrete specific 
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immunoglobulins against a specific antigen. As previously mentioned, 
although these antigens may not play a direct role in killing fungal cells , 
they appear to play an important role in aiding phagocytosis through 
opsonization. A fungal cell coated with antibodies is recognized much more 
readily by macrophages which are then able to destroy the fungus . 8-
memory cells also play a very important role in secondary infections by 
creating a significantly faster and stronger secondary antibody response 
(27) . 
Out of this general scheme of the immune system, there are several 
elements or processes which can be inhibited by immune suppressive 
agents . The anti- inflammatory corticosteroids inhibit the production and 
secretion of interleukin-1. The classical immunosuppressants such as 
cyclophosphamide inhibit proliferation and differentiation by the alkylation 
of DNA. The production of interleukins by T-helper cells which control both 
T-cell mediated as well as humoral immunity is "exquisitely sensitive" to 
cyclosporine (27) . 
Cyc/osporine. Cyclosporine is a drug which has significantly changed 
the field of organ transplants. The drug is a metabolite isolated from the 
fungus, Tolypocladium inflatum Gams, which was initially isolated in 
southern Norway. As illustrated in Figure 3, cyclosporine is a cyclic 
polypeptide derived from 11 amino acids. It is used in the prophylaxis of 
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organ tra nsplant rejection including that of the kidney, liver and heart (6) . 
Its usefulness has been widely accepted because of a much lower rejection 
rate of the transplanted organ . Cyclosporine is associated with fewer 
complications than past therapy and patients therefore recover more quickly 
from surgery ( 16) . 
Although its mechanism is somewhat unclear, certain 
pharmacokinitical properties have been characterized . The main functional 
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FIGURE 3. Chemical structure of cyclosporine. Note particularly the 
functional amino acid found in position number one . Adapted from 
Goodman and Gilman (27). 
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by the number one (71, cited in 27) . Cyclosporine's principle target seems 
to be the cyclophilins , an enzymatic family essential for the tertiary folding 
of proteins into their functional conformations . These enzymes are 
inhibited by cyclosporine at clinically relevant doses (27). 
Although the blood distribution is predictably dose dependent, 
cyclosporine is actually distributed largely outside the blood stream into the 
body . Its plasma half-life is about 6 hours (27) . Cyclosporine is 
ex tensively metabolized by the liver. This occurs through P 4 50-mediated 
oxidation of its side chains . Because of this , there is very little drug or drug 
metabolites found in the urine because most of it is excreted into the biliary 
system (27) . 
In mice, the LD50 for oral cyclosporine has been determined to be 
2329 mg/kg , whereas , the LD 50 for the IV preparation is about 148 mg/kg . 
Not only is the IV infusion more bioavailable than oral dosing but it is much 
more predictable as well . Oral administration is often erratic, requires three 
times the IV dosage and is therefore avoided in clinical medicine (6) . 
Cyclosporine's entire basis of success lies in its selective suppression 
of immune responses . The problem with most of the older 
immunosuppressive agents was that they weakened too much of the 
immune system, thus predisposing the new organ recipient to a myriad of 
infectious agents. Cyclosporine does not have such a broad response (16). 
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Clinically, this is significant because with cyclosporine, it is possible to 
selectively suppress certain portions of a patient's immune responses 
enough that rejection will not occur while leaving other portions of the 
immune system active and able to protect the body against pathogenic 
agents. Cyclosporine also plays an important role in chemotherapy 
research because it allows the specific portions of the immune system 
affected by cyclosporine to be studied . 
Specifically, cyclosporine ' s main immune target is the suppression 
ofT-helper lymphocytes. It has also been reported to affect T-suppressor 
cells to a lesser extent (29) . Lymphokine production and specifically the 
release of interleukin-2 or T-cell growth factor are therefore inhibited (6, 
40). Also, humoral responses are inhibited because cyclosporine inhibits 
the secretion of IL-3, IL-4 and IL-5 as well (27). As described above, 
lymphokines are released by the T-helper cells in order to signal other cells 
to mount a response and react against offending antigens . The effects of 
cyclosporine on decreasing lymphokine production was reported by Kasaian 
and Biron in 1990. These authors found that cyclosporine blocked T-cell 
activation in mice with a concomitant decrease in IL-2 production. Both 
CD4+ and CDS+ cells were depleted. Natural killer cell activity, however, 
was not affected. They also proposed that cyclosporine inhibits 
proliferation ofT-cells which also results in the inhibition of IL-2 production 
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(37). The mechanism of inhibition is thought to be related to the G0 or the 
G, phase of the normal cell cycle . Kasaian and Biron suggested that 
cyclosporine blocks the production of IL-2 at the level of gene transcription 
(37). Although the inhibit ion of these cells is specific , it is also quite 
reversible . Cyclosporine is not known to have any inhibitory effects on 
phagocytes or tumor cells nor does it seem to suppress bone marrow cells 
(6). 
Hiramine et al. reported testing cyclosporine in 8- 10 week old, male 
BALB/c mice . The drug was administered every other day for three weeks . 
It was given intraperitoneally at a 20 mg/kg dose . This caused atrophy of 
the medullary portion of the thymus which resulted in an overall thymic 
weight reduction . The cortex, however, was not affected as extensively 
(30). Although there was no concomitant weight reduction in t he spleen, 
cellular responses of that organ to the mitogens concanavalin A (Con A). 
phytohemagglutinin (PHA) and lipopolysaccharide (LPS) were markedly 
reduced (29) . 
Hattori et al. reported that cyclosporine specifically reduced the 
number of T-cells in both the spleen and lymph nodes (29). Hiramine 
demonstrated that spleen cells from cyclosporine compromised mice 
responded much less than did controls in their response to Con A and PHA, 
both T cell mitogens. A significant decrease was also noted in the 
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splenocyte response to LPS suggesting B-cell suppression (30) . 
The selective nature by which cyclosporine suppresses the immune 
system has also led to research dealing with autoimmune disorders . For 
example, in 1984, the FDA approved cyclosporine for testing in clinical 
trials as therapy for American juvenile-onset diabetes. This is an 
autoimmune disease in which the immune system destroys the insulin-
producing beta cells in the pancreas (16) . If administered sometime during 
the first six weeks after the onset of disease, cyclosporine can temporarily 
control the condition (27) . Work is also being carried out to test the drug ' s 
effects against uveitis , another autoimmune disease that results in 
blindness from immune assault of ocular tissues (16) . Administration of 
cyclosporine has also been shown to be effective against rheumatoid 
arthritis, psoriasis , aplastic anemia , inflammatory bowel disease, and 
glomerulonephritis (27) . 
There are also some drawbacks to the use of cyclosporine. Some 
complications include renal dysfunction, tremor, hypertension, gum 
hyperplasia and rarely , convulsions . Hypertension is fairly common. 
Anaphylactic responses, however, are believed to originate from 
polyoxyethylated castor oil, the vehicle for the drug's IV formulation (6). 
High doses are considered to be both hepatotoxic as well as nephrotoxic . 
Nephrotoxicity is noted in 25 - 75% of patients receiving cyclosporine. 
24 
Care is therefore a necessity when cyclosporine is given simultaneously 
with nephrotoxic drugs because of possible synergism. Amphotericin 8 and 
ketoconazole are also reported to increase the plasma concentrations of 
cyclosporine by reducing its metabolism and therefore decreasing its 
clearance (6, 27) . As with other immunosuppressive agents, cyclospor ine 
is noted for increasing the occurrence of neoplasia (6) as well as the 
incidence of opportunistic infections . The incidence, however, of both of 
these complications is lower than with classical immunosuppressants (27) . 
Another compl ication associated with the drug includes increased facial 
hair. Cyclosporine therapy is also expensive (16) . 
Cyclophosphamide. As a member of the alkylating drugs, 
cyclophosphamide has a fascinating history. Its precursors were first 
synthesized in 1854 and were well known as the sulfur mustards during 
World War I when they were used for chemical warfare . Until the end of 
World War II, the sulfur and nitrogen mustards were agents classified for 
use in chemical warfare . After World War II, however, extensive research 
was conducted on them and they have since led the procession into 
modern cancer chemotherapy . Cyclophosphamide is a specific drug of this 
class and is used for cancer chemotherapy . It was developed in an attempt 
to improve the neoplastic selectivity of the mechlorethamines by the 
modification of their chemical structure. Though most often utilized in 
25 
concurrence with other neoplastic drugs, it is the most widely used drug in 
its family of nitrogen mustard antineoplastic compounds (4, 18) . 
Cyclophosphamide is an alkylating agent which is metabolized in the 
liver by the cytochrome P-450 mixed function oxidases of the smooth 
endoplasmic reticulum . As represented in Figure 4, cyclophosphamide is 
hydroxylated by the hepatic cytochrome P- 450 system to produce an 
equilibrium mixture of 4-hydroxycyclophosphamide and its acyclic 
tautomer, aldophosphamide . These two intermediates are further oxidized 
to both inactive and active products. The 4-hydroxycyclophosphamide is 
enzymatically broken down to 4-ketocyclophosphamide, an inactive 
compound . Aldophosphamide is acted upon by a hepatic aldehyde oxidase 
by nonenzymatic action to form the inactive carboxyphosphamide as well 
as the active metabolites, phosphoramide mustard and acrolein . In its 
original form , cyclophosphamide is inactive and is slowly excreted by the 
kidneys. The active intermediates cause alkylation by an ali-or-none 
response. All detoxified metabolites as well as any inactive intermediates 
are rapidly excreted. The liver, as well as other normal tissues, can further 
degrade the active products . This is a protective mechanism of normal 
tissue against the toxic effects of cyclophosphamide and it is believed that 
tumor cells do not possess these same protective mechanisms. This could 
be the basis for the relative neoplastic selectivity of the drug (4, 18). 
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FIGURE 4 . The chemical structure and metabolism of cyclophosphamide 
into both inactive and active metabolic products. Adapted from Goodman 
and Gilman ( 18). 
The mechanism of action of phosphoramide mustard and acrolein is 
mainly the alkylation of DNA. These active products interfere with mitosis 
in normal and rapidly dividing tissues . Guanine residues are those most 
often alkylated . Guanine usually exists as a keto tautomer which readily 
hydrogen bonds via Watson-Crick base pairs with cytosine by three 
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hydrogen bonds. Alkylation of the nitrogen atom at position seven causes 
the purine to change to its enol form due to increased acidity. In this form 
guanine can pair with thymine . This results in both miscoding and cross-
linking of the DNA strands . Cells seem to be more sensitive in the late G, 
or the S phase of cell division. This is why the toxicity of 
cyclophosphamide is mainly selective for rapidly dividing cells in comparison 
to non-proliferating tissues . If normal DNA repair enzymes have time to 
repair the problems created by cyclophosphamide prior to its next cellular 
division, the alkylation can be reversed and may not be lethal to the cell . 
Increased activity of the DNA repair mechanisms is generally believed to be 
the mechanism of acquired resistance. High doses of cyclophosphamide 
create such extensive cross-linking that the repair mechanisms are unable 
to reverse the problems. This inhibits growing susceptible neoplasms as 
well as some normal tissue such as in the wound regeneration process (4, 
18) . 
Activity of the toxic metabolites is mainly dose-dependent and does 
not necessarily depend upon the rate at which the active intermediates are 
generated . The drug is fairly stable in aqueous solution and has a plasma 
half-life of seven hours. Because cyclophosphamide itself is biologically 
inert, it is excreted very slowly from the body . The inactive metabolites, 
however, are rapidly excreted from the kidneys. Cyclophosphamide is 
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absorbed relati vely well per os. It can also be administered intravenously, 
intramuscularly, intraperitoneally and intrapleurally . The plasma half-life is 
shortened by previous admin istration due to acquired resistance . This 
resistance is quite broad for this family of alkylating agents and cross-
resistance is a contributing factor to decreased permeability and an increase 
of substances which will nucleophilically compete with DNA for alkylation 
(4, 18) . 
Because the alkylating agents are toxic to rapidly dividing cells , t hey 
have a pronounced effect on the immune system as well. Of all the 
alkylating agents, this is particularly true of cyclophosphamide. Following 
administration, leukopenia is expected and is therefore used as a 
therapeutic monitor. The total leukocyte count is kept between 2500 and 
4000 cells /mm3 • As depicted in Figure 2 , cyclophosphamide inhibits the 
proliferation and differentiation of both cell-mediated and humoral 
immunity. Six to eight hours following the initial dose, hematopoietic 
mitosis stops and formed elements already present in the bone marrow and 
lymphoid tissue disintegrate . Lymphocytes seem to be the most sensitive. 
Therapy must often be interrupted in cancer patients receiving 
antineoplastic chemotherapy because the immunosuppression leads to 
infections with fungi as well as from bacteria and viruses. This 
intermittency of administration provides the immune cells as well as normal 
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tissues time to recover (27) . These immunosuppressive effects are 
reversible in 7-10 days. Because of this marked immunosuppression, 
cyclophosphamide has also been used to control organ transplant rejection 
as well as certain autoimmune disorders (4, 18) . 
Other problems with cyclophosphamide therapy have also been 
characterized . Secondary malignancies are one problem. These are mainly 
found in the urinary bladder or can be either myeloproliferative or 
lymphoproliferative . The drug has also been demonstrated to be 
teratogenic in mice, rats, rabbits and monkeys . Portions of the drug are 
secreted in breast milk and gonadal suppression can occur. Other 
complications include damage to the hair follicles , which often causes 
alopecia . Nausea, vomiting and dizziness are other common problems 
associated with cyclophosphamide therapy (4, 18). 
Amphotericin B. Drug description. Amphotericin B has long been 
the drug of choice in the treatment of systemic fungal infections and is still 
the most widely used drug preparation for systemic antifungal therapy . 
This is because it is fungicidal rather than fungistatic as are most other 
antifungal agents. It is a broad spectrum antibiotic that is effective against 
a variety of fungal pathogens. Amphotericin 8 is a metabolic product of 
Streptomyces nodosus, a soil actinomycete (9) and was first isolated by 
Vandeputte et al. in 1956 (68, cited in 47). It is a member of the polyene 
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antibiotics (9) and its well known stereo structure makes it a good model 
for studying membrane-enzyme interactions (64) . As shown in Figure 5, 
it is chemically characterized by its macrocyclic structure possessing seven 
conjugated carbon-carbon double bonds along one side of the structure 
making this portion highly hydrophobic, accounting for the molecules 
lipophilicity , while the other side consists of numerous hydrophilic hydroxyl 
groups. A free amino group is also contained in the structure and is 
associated with a sugar moiety (47) . Upon its discovery, its potent 
antifungal characteristics were readily noted and its usefulness has been 
very important in the limited armamentarium of antifungal drugs indicated 
OH 
FIGURE 5. Chemical structure of Amphotericin B. Adapted from Goodman 
and Gilman (9). 
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for either immune normal or immune compromised patients who have been 
predisposed to the contraction of serious , life-threatening mycoses. 
Amphotericin B is very insoluble in aqueous solutions (12) and is therefore 
given intravenously by solubilizing it in a 1:1 weight ratio with 
desoxycholate, a bile salt detergent (60 and 14, cited in 26) . Amphotericin 
B desoxycholate has been the formulation used clinically for more than 30 
years (9). 
Mechanism of action. Amphotericin B is toxic to all cell membranes 
containing sterols . Since both fungal cell membranes as well as mammalian 
cell membranes contain sterol , amphotericin B is toxic to both ( 12, 48, 62). 
The basis for both its usefulness as an antifungal agent as well as its 
toxicity to the mammalian host is due to the fact that the drug appears to 
be much more selective towards ergosterol , found in fungal cell 
membranes, rather than cholesterol which is found in mammalian cell 
membranes . The mode of action of amphotericin B is to bind to membrane 
sterols. This makes it totally ineffective as an antibiotic agent against the 
procaryotic bacteria, viruses and rickettsiae (5, 65). because of their lack 
of sterols . 
In 1968, Andreoli and Monahan suggested that amphotericin B's 
mechanism of action was the creation of cation selective pores in cell 
membranes (3). Holz and Finkelstein reported in 1970 that the addition of 
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amphotericin B to th in lipid membranes increased their permeability to 
water, ions and non-electrolytes (31 ). These were important findings for 
Cass et al. who suggested "that aggregates of polyene and sterol from 
opposite sides of the membrane interact to create aqueous pores" (p . 1 00) . 
They noted that the permeability seemed to be size dependent and 
described the "pore" as having a Stokes-Einstein radius of 4 A. This was 
determined because permeability immediately diminished with larger 
mo lecules such as glucose (20). Hamilton et al. noted in 1991 that "partial 
phase diagrams were interpreted as demonstrating that amphotericin B has 
a tendency to separate into a rigid phase within the membrane. This is 
consistent with molecular modelling considerations which suggest that 
amphotericin B may exist as oligomers in a phospholipid matrix" (26 , p. 
220) . These findings were consistent with later discoveries and have led 
to the generally accepted belief that amphotericin B interacts with the 
sterols in cell membranes to form channel-like pores. These pores create 
a "leaky" cell membrane to important molecules , the most important of 
which seem to be mono- and divalent cations (34, 48 , 52, 53) . Thomas 
et al. clarified that the disruption of membrane integrity occurs both in the 
cytoplasmic as well as in the lysosomal membranes (65) . 
One of the most important observations to support the 'pore forming ' 
theory of amphotericin B was work published in 1991 by Willumsen and 
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Boucher who noted that the addition of amphotericin B to membranes led 
to a membrane depolarization from -48 to -16 mV as well as a decreased 
resistance from 277 to 135 Ohm x cm2 (73) . Willumsen and Boucher also 
published work conducted on airway epithelia which demonstrated that 
treatment with amphotericin B depolarized cell membranes (72) . Work 
published in 1991 by Reinach et al. concerning cell shrinking after 
amphotericin B exposure also supported these findings. They noted that 
the basolateral membrane conductance as well as the basolateral membrane 
capacitance decreased concomitantly with basolateral membrane folding 
and subsequent dilatation of the intercellular spaces following amphotericin 
B exposure; both indicative of cellular shrinking . Cells exposed to the drug 
were computed to have a decreased size, 26% below that of control cells . 
In this experiment, the membranes were depolarized to a final value of -15 
mV (56). 
The method by which amphotericin B affects the membrane potential 
is by disrupting the ion gradients essential to proper cellular function. In 
1991, Bolard et al. indicated that increased permeability and ion fluxes in 
the membranes were steps which always preceded cell death (15) . As 
previously described, it is generally accepted that amphotericin B 
accomplishes this by the formation of a transmembrane pore. Hamilton et 
al. noted that the macrocyclic "hydrocarbon backbone ... forms an elongated 
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structure roughly comparable in size and shape to a phospholipid in a 
membrane" (p . 221 ). This is because the hydrophobic conjugated carbons 
associate with the hydrophobic phospholipid tails and the hydroph ilic 
hydroxyl groups associate with the sterols (26) . The accumulation of 
amphotericin B molecules in this manner creates a transmembrane pore 
wh ich Cass et al. described as a dynamic pore that continuously melts and 
reforms at equilibrium. They reported this was due to observations that 
pore format ion and dissociation were temperature dependent and at colder 
temperatures , the individual pores were more permanent than at higher 
temperatures (20) . Hartsel et al., noting that amphotericin B formed 
"barrellike pores with cholesterol" (p . 77), reported more specific evidence 
in 1991 to suggest that these pores are cation selective when added to one 
side of the membrane and anion selective when added to both sides (28) . 
Because the pores formed by amphotericin B destabilize ion gradients 
subsequently destroying membrane potentials, in 1990, Better et al. noted 
that this resulted in full activation of cationic extrusion pumps in an attempt 
to reestablish proper ion gradients . While the pumps work against the open 
pores which allow passive ion diffusion, ATP stores are rapidly utilized , 
leading to ATP depletion and rapid anoxic injury (10) . 
Jon leakage - potassium ions. The most noted problem created by 
amphotericin Band its formation of pores is the loss of the K+ gradient . In 
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1991 , Bolard et al. noted that membrane permeability to K + is the first 
event noted following exposure to the drug ( 15). lllek et al . reported in 
1991 that the loss of intracellular K+ to extracellular fluid is predictable 
from the loss of membrane potential indicating that K+ flow may be the 
major factor in destroying the potential (33). The same year, Hartsel et al. 
supported this by his finding that net K • permeability was always induced 
even at very low amphotericin B concentrations and that it was always 
more significant than Na • or c1· permeability regardless of other 
parameters , such as sterol content or which side of the membrane the drug 
was added to (28) . These results are consistent with results from other 
authors who noted the large decrease in intracellular K • and subsequent 
collapse of ionic gradients (35, 53, 56) . Results published by Raatikainen 
et al. in 1991 also noted that at concentrations above 5 t~M, amphotericin 
B inhibited the Na•, K+ ATPase (53). 
A 1991 report by Broughton et al. also noted that two amphotericin 
B resistant Candida albicans mutants demonstrated slight alterations in their 
membrane structures which made them more resistant to K• leakage. This 
was demonstrated by inducing K • leakage with a detergent. They 
indicated that the mechanism of resistance, though probably an alteration 
in the membrane structure, did not include a specific substitution of sterols 
(17) . 
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Jon leakage - sodium ions. The fact that amphotericin B inhibits the 
Na +, K+ ATPase also indicates that increased Na+ permeability also plays 
a role in the destruction of the ionic gradient. Working with toad bladders, 
Andreoli and Monahan noted aNa+ dependent loss of membrane potential 
with amphotericin B exposure . This was probably due to an increased Na + 
permeabili t y in the mucosal membrane (3). Reinach et al. noted significant 
increases in intracellular Na + concentrations following amphotericin B 
exposure (56) and Joly et al. reported that in renal proximal tubular cells , 
amphotericin B significantly depressed Na + dependent uptakes following 
one hour (35) . This could be an important reason why the nephrotoxicity 
of amphotericin B is so high . 
In a 1991 report, Jullien et al. also noted changes in the membrane 
potentials of human polymorphonuclear leukocytes following exposure to 
amphotericin B. The main reason for these changes was due to a very 
dominant influx of Na+ into the leukocytes. They noted that this Na + 
dependent depolarization was the dominant effect noted from amphotericin 
B exposure (36) . 
Jon leakage- calcium ions. In 1991, Raatikainen et al. reported that 
amphotericin B exposure also significantly affected the Ca2 + gradient in 
membranes by measuring the concentration of Ca 2 + in isolated nerve 
terminals following amphotericin B exposure. They found that amphotericin 
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B induces a Ca2 + influx through sterol containing membranes and that in 
the nerves, it increases the cytosolic Ca 2 +. This likewise increases the 
energy demand as the cell attempts to restore the proper gradient . In 
conclusion, they stated that amphotericin B forms "a channel which is leaky 
to monovalent cations such as K+ and Na+ but [makes] the plasma 
membrane permeable also to Ca 2 + .... The polyene-cholesterol channels 
increase the ionic permeability of synaptosomal plasma membrane(s) 
leading to the depolarization of the plasma membrane" (53, p. 1349) . 
In 1990 Wong et al. noted similar results following amphotericin B 
exposure to a membrane in which an electrical gradient had been 
established . There was a steady increase in intracellular free Ca 2 + over a 
30 minute period with a concomitant loss of membrane gradient (74). In 
1991, Bolard et al. further noted that amphotericin B induces Ca2+ leakage 
much more readily in membranes containing ergosterol rather than those 
containing cholesterol. In some cholesterol containing membranes such as 
lymphocytes, there was no leakage (15). 
In 1991, Tolins and Rai reported that when using amphotericin B, 
cotreatment with diltiazem, a calcium channel blocker, prevented renal 
vasoconstriction and decreased the glomerular filtration rate in the rat . 
When amphotericin B was used alone, serum creatinine rose markedly and 
glomerular filtration as well as renal plasma flow likewise fell. Cotreatment 
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with diltiazem, however, curbed the adverse hemodynamic effects in the 
kidneys which resulted from amphotericin B exposure indicating that Ca2 + 
leakage is an important factor in renal toxicity (66) . 
Jon leakage - chloride ions. In 1991, Reinach et al. reported that 
upon amphotericin B exposure, Cl- transport decreased significantly (56). 
Ergosterol vs. cholesterol. It has already been noted that 
amphotericin B binds to sterols contained in both fungal and mammalian 
cell membranes . The reason amphotericin B is a good fungicidal agent, as 
well as a toxic drug to mammalian cells, is due to its apparent affinity for 
ergosterol containing membranes as compared to membranes containing 
cholesterol (34, 521 . In 1991, Hartsel et al. suggested that there could be 
a different mechanism of action between amphotericin B and the two 
sterols . They also noted that sterols are necessary for amphotericin B 
activity because they increase the pore size in the membrane which allows 
larger ions such as Ca 2+ to pass through (28) . Bolard et al. supported the 
different mechanism theory mentioned above by noting that the circular 
dichroism (CD) and absorption spectra for ergosterol and cholesterol 
containing membranes exposed to amphotericin B were totally different. 
They further noted that the formation of single channel pores by one-sided 
addition of the drug only occurred in membranes containing ergosterol . It 
was also found that the affinity of amphotericin B to membranes containing 
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ergosterol was much higher than for those containing cholesterol. When 
amphotericin B was added to each membrane, the ratio of amphotericin 
B/cholesterol was 0.025 whereas the amphotericin B/ergosterol ratio was 
1. It was suggested that the 1:1 amphotericin B-ergosterol complexes 
aggregated in the membrane such that transmembrane pores were formed 
up to a thickness of 24 A (15) . 
The most important discovery, however, was that there was a 
critical concentration found (5 x 1 o·7 M at 37" C). below which 
amphotericin B would not bind to a cholesterol-containing membrane 
whereas there was no such lower limit for binding with ergosterol -
containing membranes . When the critical amphotericin B concentration 
was reached in membranes containing cholesterol, K+ permeability was 
induced . At this same critical concentration, it was also noted that the 
amphotericin B molecules began to self-associate . In 1991 , Hartsel 
proposed that amphotericin B monomers are not long enough to traverse 
the mammalian cell membranes in order to form transmembrane channels 
but that a head-to-tail binding of amphotericin B monomers to form 
oligomers would increase their length enough to do so (28) . 
It has also been reported that fungal mutants which have become 
less susceptible to amphotericin B can be isolated by passing certain fungi 
through cultures containing the drug. The major difference which these 
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mutants exhibit compared to their non-resistant ancestry is a decreased 
amount of ergosterol found in their cell membranes (9). 
Pharmacokinetics. The plasma half-life of amphotericin 8 is 24 hours 
(5) . Because of this , plasma concentrations, once reached, are well 
maintained. The drug binds readily to tissues after being released in the 
blood from its desoxycholate complex . The actual elimination half-time is 
around 15 days. Peak plasma concentrations of 2 - 4 ,ug/ml are produced 
by the administration of between 1 - 5 mg/day with a gradual increase to 
0.65 mg/kg /day. This is ideal since various fungi are sensitive to 
amphotericin 8 at concentrations of 0 .03 - 1.0 ,ug/ml in vivo (5). One 
drawback of the drug is that it is poorly absorbed through the 
gastrointestinal tract. Fujita et al. published work in 1991 wherein they 
utilized this characteristic to differentiate between intestinal candidiasis and 
invasive infections. This was possible because oral amphotericin B is only 
reliably effective against colonization within the gastrointestinal tract (25). 
Oral dosing of 3 .0 mg/day will yield plasma concentrations of only 0 .1 -0.5 
,ug/ml. Much higher plasma concentrations are achieved intravenously 
using 1.0- 5.0 mg/day and increasing to 0 .65 mg/kg which will yield peak 
plasma concentrations (5). Depending on the source of investigation, the 
maximum tolerated dosage is between 0 . 75 - 1.5 mg/kg (9, 2) . Sanders 
et al. noted that 0.25 mg/kg was well tolerated but that at 1.5 mg/kg, half 
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of the patients experienced nausea, vomiting and chills (59) . 
Knowledge concerning the other pharmacokinetical parameters of 
amphotericin B is very limited . Tissue distribution and possible pathways 
of actual drug metabolism are relatively unknown beyond the fact that a 
third of the drug can be recovered at autopsy with the highest 
concentrations demonstrated in the liver and spleen . Smaller amounts are 
also found in the kidneys and lungs (9) . In 1991, Sanders et al. noted that 
plasma concentrations of amphotericin B increase linearly with increased 
infusion but quickly dropped off following discontinuation of drug 
administration. This indicated that tissue distribution is rapid (59) . 
Casaccia et al. noted in the same year that the amount of amphotericin B 
found in the spleen and brain was directly proportional to the dose 
administered (19). Little else has been reported. 
Antifungal spectrum of activity. The antifungal affects of 
amphotericin B are well established. It is used as the drug of choice in 
many situations where other drugs are not nearly as effective . 
Amphotericin B is active against Candida sp., Cryptocuccus neoformans, 
Histoplasma capsulatum, Blastomycoses dermatitidis, Aspergillus sp ., 
Torulopsis glabrata, Paracoccidioides braziliensis, Coccidioides immitis, and 
other organisms such as those which cause mucormycosis. It is also 
somewhat active against Leishmania braziliensis and Naegleria fowleri, both 
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protozoan parasites (9) . 
One of the most salient features is that although it is fungistatic at 
low dosages, at higher doses, it is fungicidal. This is, of course, dependent 
upon both clinically achievable body concentrations as well as the 
organism's susceptibility to the drug (5). The ability to achieve fungicidal 
concentrations is the reason why amphotericin B is highly effective and the 
drug of choice in systemic infections involving cancer patients and other 
immunocompromised individuals (48). In 1988, Janoff et al. labeled its 
usefulness when he stated that it is "the drug of choice for a variety of 
fungal infections that were almost always fatal prior to its induction" (34, 
p. 6122). Prior to the availability of amphotericin B, some mycoses were 
invariably fatal (42). 
A 1991 report by Walsh et al . indicated that amphotericin B should 
sometimes be used even if a deep mycosis is even only suspected. Such 
a case would be indicated when a granulocytopenic patient with a 
persistent or recurring febrile condition does not respond to appropriate 
antibacterial medications . This would indicate the high risk of a invasive 
fungal infection. Studies indicate that prompt therapy with amphotericin 
B is efficacious in such situations in order to ensure early treatment of such 
serious fungal complications (70) . 
Immune modulation - augmentation. Of more interest than the 
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antifungal effects of amphotericin B to this investigation is its 
immunologically adjuvant-like characteristics ( 12) which have allowed many 
researchers to class ify it as an immunostimulant. Recalling that the 
possible features of an immunological adjuvant are : a) that it increases the 
surface area of the antigen, and/or b) that it prolongs the body's retention 
of the antigen allowing the lymphoid system more time to access t he 
antigen (8) will help in understanding the possible mechanisms of immune-
augmentation . The actual mechanism of stimulation by amphotericin B is 
currently controvers ial and unknown . 
In 1986, Vecchiarelli et al. reported that the drug protected mice 
against Candida albicans by a mechanism independent of its normal 
chemotherapeutic pathway (69) . Blanke et al. reported as early as 1977 
that amphotericin B augmented both humoral as well as cell-mediated 
immune responses (12) . More specifically, Lopez-Berestein et al. stated in 
1983 that amphotericin B augmented both B-andT- cell functions including 
the activation of macrophages (46). 
The hypothesis that is generally accepted is that amphotericin B acts 
nonspecifically in potentiating host resistances (43) . Studies by Vecchiarelli 
et al. in 1986 suggested that the mechanism is activation rather than 
proliferation since the spleen cellularity remained unchanged following 
amphotericin B exposure (69) . In 1977, Blanke et al. demonstrated that 
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administrat ion of the free drug to murine species will significantly lower the 
thymic weights and increase the splenic weights . Weights of other 
lymphoid t issue are affected as well. When used with other 
immunostimulators, augmentation is synergistic for both particulate and 
soluble stimuli ( 12) . 
In two separate ex periments, the prophylactic capabil it ies of 
amphotericin B were well described . In 1973, Thomas challenged mice 
w ith a bacterial pathogen , Listeria monocytogenes, to demonstrate the 
immunopotentiating effects of amphotericin B. When given prior to biotic 
challenge, amphotericin B was reported to have actually stimulated host 
resistance. Specifically, when injected 24 hours prior to challenge, 
amphotericin B decreased the mortality to fifty percent that of control 
groups . Control groups included mice infected with L. monocytogenes 
which only received glucose solutions both 24 hours prior to challenge and 
24 hours post challenge. One group of mice challenged with L. 
monocytogenesalso received amphotericin B 24 hours post challenge . This 
was done to rule out any possible antibiotic effects of amphotericin B due 
to drug residues even though the drug has no therapeutic efficacy against 
bacteria because of the lack of sterols in their plasma membranes . In 
addition, fewer bacterial colony forming units were quantified in the liver 
and spleen of mice receiving chemotherapy prior to challenge as opposed 
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to control models or those receiving drug after inoculation with Listeria . In 
vitro tests also substantiated the fact that amphotericin B has no 
therapeutic efficacy by not inhibiting growth of the bacteria (65). Other 
researchers have reported similar results using the same parameters (43) . 
Another example of the immunopotentiating affects of amphotericin 
B was demonstrated in several experiments using oncogens. In 1974, 
Medoff demonstrated that prophylactic treatment with amphotericin B 
affected the survival of mice with a highly virulent transplantable leukemia . 
The survival of those groups receiving amphotericin B exposure prior to the 
transplant demonstrated a significantly higher survival rate as compared to 
control animals which did not receive amphotericin 8 (43) . Amphotericin 
B exposure also provided long term cures in AKR mice . These mice 
reta ined their resistance to the original strain of leukemia though they were 
still susceptible to others ( 12). It also delayed the occurrence of 
spontaneous lymphoma in the AKR strain (43). Because of these results, 
it has been hypothesized that amphotericin B may be a "useful auxiliary 
chemotherapeutic agent or immunoadjuvant in the treatment of human 
malignancy" ( 12) . 
Amphotericin B has also been reported to specifically augment 
humoral responses (61 ). Several sources have reported an augmentation 
of 8-cell functions (43 , 49, 64) . Medoff indicated that the drug augments 
46 
the lgM to lgG switch (12) which is important since lgM antibodies are the 
first to a reaction site but lgG antibod ies are the most predominant . 
In 1979, Shirley reported that amphotericin B enhanced contact 
sensitivity on specific cell -mediated effector functions suggesting that 
amphotericin B stimulates T-cell mediated responses (61 ). In 1985, Mehta 
et al . reported t hat amphotericin Bat a 2 .0 pg/ml dose activated monocytes 
and suppressor T-cells in human peripheral blood mononuclear preparations 
(49) . Alte red T-cell activity is evidenced by enhanced contact sensitivity 
and an increased proliferative response (64) . 
One of the major immunopotentiating effects of the drug is due to 
macrophage activation . Vecchiarelli reported in 1986 that amphotericin B 
specifically augments macrophages against in vivo fungal infections. In this 
report , the increased phagocytic activity seemed to be the principle target 
of modulation which had both quantitative as well as kinetic properties . A 
single dose of 10 mg/kg prior to challenge was just as effective as five 
daily treatments at 2 mg/kg, twelve days through eight days prior to 
challenge. Activity was lost, however, when the drug was given on an 
alternate day basis. In this same study, no additional benefits were derived 
at doses of 50 mg/kg and the threshold value was determined at 10 pg/ml 
(69) . This type of contact sensitivity is typical of a delayed-type 
hypersensitivity reaction ( 61 ) . 
47 
One explanation for this type of activation was presented by Beccari 
et al. who reported in 1991 that murine adherent spleen cells were 
activated against candida/ infections by exposure to amphotericin B. It was 
noted that this was due to the specific st imulatory secretion of 
hexosaminidase, a lysosomal enzyme. This stimulation increased the 
activity of these cells ' cand idacidal activity (7) . 
In another study by Lin in 1977, peritoneal macrophages of treated 
mice showed a higher phagocytic and antibacterial activity than 
macrophages from control mice following amphotericin B exposure. In this 
study, there was an eight-fold increase by day four in the splenic content 
of limited stem cells of both macrophages and granulocytes . Also , there 
was a three-fold increase in the number of pluripotent hemopoietic stem 
cells or colony forming units in the spleen. Amphotericin B also induced 
large numbers of peritoneal colony forming cells in the peritoneum and 
caused a significant rise in the serum level of the colony-stimulating factor . 
The increase in phagocytic and antibacterial activity of phagocytes and their 
precursor cells was evident in the hemopoietic organs. The same results 
were observed in pure macrophage preparations in vitro . These results 
were obtained by the ingestion of polystyrene beads . Because there was 
an increase in phagocytic activity when using purified macrophage 
preparations in vitro, the response was likely primary . There was no 
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significant alteration in the number of blood monocytes but a transient 
increase in the proportion of neutrophils was exhibited within 24 hours 
(43). 
It should be noted that there are several different means of 
increasing macrophage activity. First, is the activation of preexisting 
mature tissue macrophages. A second option would be to stimulate the 
production of macrophages . Another possibility would be the movement 
of "active macrophages" to the site of action and a fourth would be a 
combination of the above . It was not clear from Lin ' s results if the increase 
in splenic content was due to a migration from bone marrow or if it was 
due to replication of preexisting cells or a combination of the two . It was 
established that amphotericin B is capable of inducing an acute, local 
inflammatory reaction by activating or attracting macrophages to the site 
of inflammation . Monocytes, precursors of tissue macrophages, migrate 
to sites of inflammation. Interestingly, the blood monocyte levels remained 
unchanged but the splenic and bone marrow granulocytes and monocytes 
increased after amphotericin B exposure . It is clear from these results that 
amphotericin B may stimulate the function and supply of certain classes of 
cells that belong to the mononuclear phagocyte system (43). The 
mechanism of activation may be through a capacity to cause mononuclear 
cells to secrete interleukin-1 and tumor necrosis factor. This has been 
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noted both in human monocytes and murine macrophages in vitro. In both 
instances, the response was observed to be pyrogenic (9) . 
It is unknown if the effect of amphotericin B on macrophages is 
primary or if it is secondary by sensitizing and stimulating lymphocytes to 
produce lymphokines which in turn would sensitize the macrophage 
population (65) . It is important to note, however that the drug does 
augment the phagocytic and antigenic activity of macrophages in vivo (49) . 
This applies to enhanced tumorcidal activity as well (64) . Increased 
phagocytic function was noted following both IV and IP injection of 
amphotericin B (43). 
Blanke et al. characterized this somewhat ambiguous and confusing 
topic by generalizing that "the adjuvant activity of amphotericin B could 
reside with the T cell, B cell, or macrophages or by enhancing the 
physiological cellular interactions" (12, p. 189) . 
Immune-modulation - suppression. In contradiction to the reports 
about amphotericin B's ability to augment the immune system, some 
researchers have indicated that amphotericin B actually suppresses 
immunity . In 1985, Mehta et al. stated that its effects partially inhibited 
antibody production in vivo. They also stated that high concentrations 
inhibited the blastogenic response of T-cells (49). From histological 
evidence, Blanke et al. postulated that the effect was the depletion of 
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cortical cells from the thymus which may have been due to differing 
amounts of cholesterol content in the plasma membranes on the less 
mature T-precursor cells (12). Highly suppressive effects of macrophage 
differentiation at 1 .ug/ml were also reported (49) . 
Toxicity. Because of its interaction with cholesterol in eukaryotic 
membranes, amphotericin B, as previously described, is toxic to mammalian 
cells . This severely limits its clinical usefulness because of a very narrow 
therapeutic index marginated by its severe side effects. Recalling that at 
low doses, amphotericin B is fungistatic whereas at high doses it is 
fungicidal, the problems associated with toxicity are further complicated 
because in reality, the therapeutic dose is very close to the toxic dose . This 
often makes the treatment of disseminated fungal infections futile, 
especially in cancer patients who already exhibit granulocytopenia (46). 
The recommended indication of the drug is limited for the treatment of 
patients with "progressive and potentially fatal fungal infections" (5, p. 
214 7). Because of the high-dose therapy required in the immune 
compromised host, the toxicity of amphotericin B is even more limiting 
(34) . 
This toxicity is mostly related to the kidneys, which only excrete the 
drug very slowly. Excretion will actually continue up to seven weeks post 
drug therapy (5). Of the small amount excreted in the urine, only a portion 
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is in the act ive form . Specific pathological effects of the drug include 
decreased renal function along with abnormal urine sediment in over 80% 
of the patients . Thickening and fragmentation of the glomerular basement 
membrane, hypercellularity, fibrosis, hyalination of the glomeruli and 
nephrocalcinosis are also associated complications (9) . Renal parenchymal 
edema, diffuse interstitial edema (46) and degeneration and atrophy of the 
tubules are also characteristic . Acute hepatic failure with associated 
jaundice and hepatocellular dysfunction are also associated with toxicity . 
This is exhibited by the toxic degeneration of hepatocytes (9). 
Recalling that the maximum tolerated dose ranges between 0. 75 -
1 .5 mg/kg , it can now be better understood why doses greater that 1 .6 
mg/kg result in acute toxicity . Outwardly, a dosage greater than 1. 6 mg/kg 
in mice is characterized by a spastic reaction followed by cardiorespiratory 
arrest. When Lopez-Berestein demonstrated such a response in 1983, 
autopsies failed to demonstrate the cause of death. The LD,o was 
determined at 1.2 mg/kg (46). Even at single doses of 300 - 500 JJg, 
amphotericin B has been reported to have caused ruffled fur and reduced 
activity for several days following injection in mice (12). 
Liposomal Drug Delivery Systems. One way of reducing the toxic 
effects of a drug may be to find a different means of drug delivery. Much 
time and effort is currently underway in this area of research. One method 
52 
of altering drug delivery is by incorporating a drug into lipid complexes. 
Because of the similarity between biological membranes and liposomes 
(41), liposomal incorporation has been demonstrated to alter the 
pharmacokinetics, tissue distribution, metabolism and the therapeutic 
efficacy of drug systems (48) . 
Lipid vesicles are easily prepared. They are also biodegradable and 
nontoxic (46) . Their distribution and pharmacokinetics can be modified by 
altering their lipid composition , size, charge and membrane fluidity (46) . 
Another important feature is that in vivo effects can be mimicked in vitro 
(48). Liposomes have been used as carriers for chemotherapeutic agents, 
enzymes, immunostimulators as well as genes (41, 46) . 
The driving force for the formation of a phospholipid bilayer is 
entropic . Because the individual phospholipid molecules are hydrophobic, 
many such molecules will spontaneously group together when placed into 
an aqueous medium . Though this results in a seemingly more ordered 
state, the net result is a large increase in solvent entropy because water 
molecules are no longer bound to the individual hydrophobic molecules . 
This large increase in solvent entropy overcomes the loss of randomness 
due to the association of the phospholipid molecules . These molecules bind 
by a large number of van der Waals forces within their interior. As 
illustrated in Figure 6, they associate such that their hydrophilic heads are 
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exposed to the aqueous medium and their hydrophobic tails are buried 
within a newly formed bilayer (41, 55) . Due to the hydrophobicity created 
by the conjugated carbon-carbon double bond system of amphotericin B's 
macrocyclic structure, phospholipid layers will associate around the drug 
itself. Though cell membranes are somewhat more complicated versions 
of a phospholipid bilayer, they exist due to the same entropic and 
hydrophilic and hydrophobic forces previously described. 
hydrophobic tails 
phospholipid bilayer 
FIGURE 6. Basic structure of a phospholipid bilayer. Note the orientation 
of the hydrophilic heads and hydrophobic tails. Adapted from Rawn (55) . 
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Amphotericin B is a drug that has been complexed with lipids to 
make liposomal amphotericin B. Incorporation of amphotericin B into these 
phospholipid bilayers will have a definite impact on the drug's association 
with cell membranes . The use of liposomes in drug delivery systems has 
made a significant improvement in the drug ' s efficacy by reducing its 
toxic ity . In 1988, Janoff et al. , reported that the incorporation of 
amphotericin B into lipid complexes produced a "significant attenuation of 
toxicity with little compromise to efficacy" (34, p. 6122) . The liposomes 
themselves, are characterized by a fairly low level of toxicity which ranges 
between 400 - 800 mg/kg . When treated with lower doses of the pure 
lipid , mice demonstrated the same survival rates as controls (46) . 
The mechanism of drug delivery is obscure and poorly understood 
(46, 34) . It is thought that a difference exists in the structural interaction 
of amphotericin B with the host cell membrane when incorporated into a 
lipid layer. Janoff et al. observed that the aggregates of liposomal drug, 
"which are highly ordered and limit the aqueous diffusion of amphotericin, 
provide a simple structural rationale for the lipid dependent toxicity 
attenuation of amphotericin" (34, p. 6126) . Part of the increased 
therapeutic efficiency may be due to increased and prolonged tissue 
concentrations when associated with liposomal delivery (46). 
Liposomal Amphotericin B. Pharmacokinetics. There has been 
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intense research to reduce the toxicity of amphotericin B to mammalian 
cells while retaining antifungal potency . One of the methods under the 
most intense investigation is the incorporation of the free drug into 
liposomal vesicles to alter the method of drug delivery . Hamilton et al. 
noted that amphotericin B "is well suited to liposomal format since it does 
not dissolve beyond 1o-7 M in water at physiological pH and associates with 
lipid bilayers" (26, p. 220). 
So far, the results have been impressive. Joly et al. reported that K+ 
release and Na+ dependent up-takes were unaffected by high 
concentrations (80 t~Ml of liposomal amphotericin B independent of the 
different types of phospholipid used (35) . Though Peterson et al. agreed 
that the effects of liposomal incorporation are protective, they noted in 
1991 that some lipid compositions showed more effectiveness in reducing 
host toxicity. After several different trials, they found that using 
dimyristoylphosphatidylcholine/dimyristoylphosphatidylglycerol/amphotericin 
Bat a 7:3:1 mole ratio, created an increased tendency for the drug to bind 
to ergosterol instead of to cholesterol. They concluded that this form of 
drug delivery maintained antifungal potency while reducing side effects 
because of decreased activity toward cells containing cholesterol. The 
mechanism for altered activity due to liposomal incorporation is unknown 
(52). 
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It is interesting to note that when the liposomal format was altered 
to include egg phosphatidylcholine, there was a 1 00-fold increase in the 
amount of K + that leaked to the outside of the cells, even at 20% of the 
orig inal amphotericin B concentration used in the 7 :3 :1 liposomal format 
described above . This less favorable type of liposome "as well as [the] 
micellar amphotericin also (showed) a slight selectivity towards cholesterol-
containing vesic les over ergosterol" (52, p. 165). 
The incorporation of free amphotericin B into multilamellar liposomes 
in the 7 :3:1 system resulted in reduced toxicity with no loss of antifungal 
potency (34) . For example, free drug will cause the lysis of RBC ' s and 
other mammalian cells in the ,ug/ml range . When incorporated with the 
liposomes in vitro, however, amphotericin B did not cause the same lytic 
effects w ith no consequent loss of antifungal properties . This increased 
therapeutic index suggested that the difference is a change in the drugs 
ability to interact with mammalian cell membranes rather than differences 
in pharmacokinetics or drug distribution (48) . Surprisingly, a low density 
amphotericin B lipid complex produced an LD,0 at 7.5 mg/kg whereas the 
high density amphotericin B lipid complex yielded a higher LD,0 of 11 .2 
mg/kg (34). Mice treated with empty liposomes showed no difference in 
survival compared to controls (46). 
In 1990, Ahmad et al. noted that including cholesterol in the 
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liposomal mixture could influence the distribution of amphotericin B. It was 
noted in infected mice that the addition of cholesterol to 
phosphatidylcholine and phosphatidylcholine /phosphatidylserine liposomes 
increased the amount of drug delivered to all organs . This could indicate 
a possible increase in the therapeutic benefit of including cholesterol in the 
liposomal format (1 ). 
There is currently no explanation for why the incorporation of 
amphotericin B into lipid complexes would alter its interaction with 
mammalian cell receptors without altering the relationship or at least the 
effects on the ergosterol of fungal membranes. The main importance of the 
effects as stated by Janoff et al. are that "the nonliposomal-lipid-stabilized 
aggregates of amphotericin are responsible, at least in part, for the toxicity 
attenuation that has been widely reported to result from the incorporation 
of this drug into intact vesicles" (34, p. 6126) . 
Antifungal spectrum of activity. As previously mentioned, liposomal 
amphotericin B probably reacts differently with the cholesterol, 
characteristic of mammalian cell membranes, than amphotericin B but has 
the same net effect against fungal membranes. This has been 
demonstrated by the fact that the lipid complexed drug did not lyse red 
blood cells even at high concentrations but was shown to be equally 
effective in killing fungal cells. It has also been demonstrated to be 
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equipotent against disseminated candidiasis in mice (48) . This is true for 
similar concentrations for both drug preparations . It is also possible to 
exceed the therapeutically achievable concentrations of free drug, however, 
which markedly improves the survival rate. Specifically, at 0.8 mg/kg , the 
lipid complexed drug had similar survival rates as animals treated with free 
drug (46). It is possible to exceed the LD,0 for free amphotericin which 
markedly improves the survival rate for mice infected with candidiasis (48). 
At doses greater than 2.4 mg/kg abscess formation from Candida albicans 
on the kidney, spleen and liver were not as evident as with the free 
amphotericin B at lower doses which had to be maintained in order to avoid 
toxicity (46) . 
In a 1991 publication , Boggs et al. reported that the liposomal form 
of amphotericin B did not inhibit the proliferation of freshly obtained, 
antigen-specific T-lymphocytes from lymph nodes as much as did 
amphoteric in B. Different results were obtained, however, for cultured T-
cell lines. In these preparations, liposomal amphotericin B significantly 
decreased the effects in comparison to amphotericin B ( 13). 
Davidson et al. also reported in 1991 that the liposomal format may 
be an effective way to target amphotericin B towards macrophages in 
visceral leishmaniasis . In this disease, it is the macrophages themselves 
that are infected by this protozoa . They describe the successful outcome 
59 
of treating a patient with liposomal amphotericin B (AmBisome) who 
suffered from a multiply drug resistant lieshmaniasis infection . It was also 
noted that this drug preparation is extremely effective therapy against 
leishmaniasis in experimental animals (22). 
The reason why liposomal amphotericin B seems to be an effective 
way of targeting the actual drug to the macrophages is probably because 
macrophages have a propensity to ingest liposomes . Since this is the case, 
it would be possible to treat diseases which involve macrophages more 
effectively with liposomal delivery . In the case of fungal infections, this 
could be critical. The liver, spleen and lungs are all frequently targeted by 
systemic fungal infections. Liposomal incorporation would, therefore, help 
target amphotericin B to the Kupffer cells, splenic and alveolar 
macrophages and aid in the elimination of an infection (41) . 
There have also been reports that liposomal amphotericin B is less 
effective than the regular form of amphotericin B. A 1991 report by Ralph 
et al. indicated that the in vitro fungicidal activity of liposomal amphotericin 
B was less than that of amphotericin B (54). 
Immune-modulation. Mehta et al. reported that encapsulation of free 
drug into lipid complexes protected certain immune parameters from 
inhibition (49). These effects were reported to specifically protect 
macrophages and T-lymphocytes from the toxicity or immunosuppressive 
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effects produced by free amphotericin B. These , as previously stated, are 
essential immune parameters in host resistance to fungal infections. It was 
also reported that liposomal amphotericin B did not affect the blastogenic 
response ofT-cells and allowed a functional cellular state to be maintained. 
It was observed, however, that the liposomal preparation partially 
suppressed 8-cell functions which in turn suppressed antibody production 
in vivo . The empty liposomes seemed to be the cause of this suppression . 
Little addit ional immunosuppression was observed (49) . 
Toxicity. The quality which has brought so much attention to 
liposomal amphotericin 8 is that it reduces the toxicity to mammalian cells 
while mainta ining antifungal activity (49) . In 1984, Mehta demonstrated 
that amphotericin B can be readily transferred from liposomes to fungal 
cells but not to mammalian cells . It appeared that the encapsulation 
seemed to sequester or isolate the drug in a manner that made it 
unavailable to mammalian cells but readily available to and toxic against 
fungal cells (48). 
The new formulation's reduced toxicity facilitated the use of higher 
concentrations of amphotericin 8 without the pathological or biochemical 
abnormalities previously discussed (46) . Liposomal amphotericin 8 showed 
little toxic affects even at ten fold dosage concentrations of free 
amphotericin 8 (49) . Another report indicated similar results when 
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liposomal amphotericin 8 was given at twelve times the dosage of the free 
drug. Neither the maximal tolerated dose nor the LD,0 were reached at 12 
mg/kg (461 . Another report by Miyazaki et al. in 1990 listed the LD 50 in 
mice infected with candidiasis as 10.0 mg/kg for liposomal amphotericin 8 
whereas the LD 50 for amphotericin B was 3 .0 mg/kg. In this same study, 
50% of the infected mice died from the candidiasis while receiving 0 .8 
mg/kg of amphotericin B. This was the highest dose tolerated without 
acute lethality from toxicity . Mice rece iving liposomal amphotericin 8 at 
5.0 mg/kg were all alive after 42 days . This is a further indication that the 
reduced toxicity of liposomal amphotericin 8 could be very important in 
treating systemic mycoses such as cand idiasis (501. 
An important mechanism of reducing the toxicity may stem from the 
fact that liposomes do not easily enter the kidneys. This is probably due 
to the size of the liposomes. Whatever the reason, however, the end result 
is reduced toxicity from the fact that less drug enters the kidney which 
results in the overall attenuation of renal toxicity (41 ). 
Work published in 1991 by Longuet et al. , however, warned against 
overconfidence regarding these protective qualities . They noted that 
although the renal tubular toxicity was greatly attenuated when 
administering repeated low doses (1 .5 mg/kg/day) of a liposome 
encapsulated amphotericin 8, this was not the case with higher doses (3 .5 
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mg/kg /day) . It was their recommendation to closely monitor the tubular 
renal functions as well as the electrolyte serum values in patients receiving 
liposomal amphotericin B (44) . 
A 1990 report by Joly et al. noted that where amphotericin B 
disrupted both the K + and Na + dependent ion gradients , the incorporation 
of the drug into a liposomal format left both of these gradient unaffected . 
This protection was unaltered by the type of liposome used (35) . 
Prophylaxis in murine disseminated candidiasis. Liposomal 
amphotericin B is also reported to augment immune functions when given 
prophylactically . In an experiment using Candida cells, Mehta 
demonstrated that adding the liposomal drug prior to fungal challenge 
seemed to augment the antifungal capabilities of the drug. The mechanism 
of action was not determined (48) . In 1983, Lopez-Berestein et al. 
reported that liposomal amphotericin B is superior to free amphotericin B in 
the protection of mice against subsequent challenge (46) . In 1984, Lopez-
Berestein et al. demonstrated that when given prophylactically in doses 
greater or equal to 2 mg/kg, the survival rate increased significantly in 
neutropenic mice infected with Candida albicans. These animal models 
were immunosuppressed using cyclophosphamide on days negative two 
and zero of the infection. One hundred percent of the control mice 
receiving no liposome-encapsulated amphotericin B died by day eight. Mice 
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receiv ing 2 mg/kg of liposome encapsulated amphoteric in Bon day negative 
two along with the cyclophosphamide showed 83% survival by day 25 . 
One hundred percent of the mice receiving 4 mg/kg also on day negative 
two were still alive by that time. Mice receiving 2 mg/kg showed renal 
infection, both microbiological and pathological studies failed to 
demonstrate Candida in those mice receiv ing 4 mg/kg . This was an 
important step in the evaluation of the liposomal drug as a prophylactic 
agent used in immune-compromised models (45) . 
Clinical results. Clinical results from the treatment of pat ients with 
the liposomal drug are now showing further promise in the treatment of 
various mycoses . Bjorkhow m et al. published a case history in 1991 of a 
patient suffering from granulocytopenia , acute undifferentiated leukaemia 
and hepatosplenic candidiasis. Neither amphotericin B or 5-flucytosine was 
efficacious because both were refractory and the patient suffered severe 
side effects specifically from amphotericin B. The patient was 
consequently given a liposomal form of amphotericin B which had vesicles 
made of lecithin , cholesterol and stearylamine in a 4 :3:1 ratio . With two 
different regimens of therapy, the second following a three month relapse, 
the patient recovered from the infection with no acute side effects . Only 
a moderate state of hypokalemia was noted (11 ). 
In another case history reported in 1990 by Rosti et al. regarding an 
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allogeneic bone marrow transplant patient who suffered from Candida 
tropicalis , therapy with liposomal amphotericin B was again successful. 
The drug was indicated because of the ability to administer large doses. 
This was the factor which was attributed for the successful outcome (58). 
Tollemar et al. noted in the same year that a nine month old boy was also 
treated with liposomal amphotericin B (AmBisome) with a successful 
outcome . The patient suffered from candidemia following a liver transplant 
(67) . 
Other cases have also been reported . A 1991 report by Coker et al. 
noted that a patient suffering from cryptococcal meningitis was 
successfully treated with liposomal amphotericin B following failure to 
resolve the infection with fluconazole of conventional amphotericin B 
therapy (21) . Another 1991 report by Fisher et al. described the first case 
of liposomal amphotericin B being used to treat a case of advanced 
rhinocerebral mucormycosis associated with diabetes. The condition was 
successfully treated with liposomal amphotericin B in conjunction with 
surgery and supportive therapy (24) . 
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MATERIALS and METHODS 
Immunosuppression of Mice. Splenocytes from 8-1 0 week old 
BALB/c females (Simonsen laboratories, Inc ., Gilroy, California) were 
utilized in the viability, lymphocyte proliferation and macrophage activation 
interleukin-1 production assays . Mice were immunosuppressed in vivo by 
injecting 50 mg/kg of cyclosporine (Sandlmmune, IV; Sandoz 
Pharmaceuticals Corp., East Hanover, New Jersey) IV into the tail vein 24 
and 48 hours prior to euthanasia and splenocyte collection. The 
cyclosporine was prepared by diluting cyclosporine in 5% Dextrose 
Injection, USP (U.S . Pharmacopeia) (Abbott Laboratories, North Chicago , 
Illinois) immediately prior to administering it to the mice . One milliliter of 
stock cyclosporine (50 mg/ml) was diluted in 24 ml of 5% dextrose and the 
injection volume per 20 gram mouse was 0 .5 mi. 
Mice receiving immunosuppression with cyclophosphamide (Sigma 
Chemical Company, St. Louis, Missouri) were given intraperitoneal (IP) 
injections of 100 mg/kg, in vivo, five days and 24 hours prior to euthanasia 
and splenocyte collection . The cyclophosphamide was reconstituted by 
adding 10 ml of distilled deionized water to 0.1 grams of 
cyclophosphamide. The solution was then filter sterilized using a 0.2 11m 
pore filter. Each 20 gram mouse received 0 .2 ml of this solution. 
Mice were euthanized according to the recommendations of the 
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American Veterinary Medical Association (AVMA) Panel on Euthanasia (63). 
Cervical dislocation was used because it left all tissues drug residue free . 
The panel recommended that animals receive light anesthesia to sedate 
them prior to cervical dislocation . Prior sedation was not used, however, 
because of reports by Howard et al. in 1990 who demonstrated that 
various immunological parameters are effected by different types of 
sedation and euthanasia other than by cervical dislocation. In Howard ' s 
study, mitogen induced lymphocyte proliferation, as well as the stimulation 
of cytolytic T-lymphocytes, was compared in animals euthanized by cervical 
dislocation without sedation as the control and using methoxyflurane or 
pentobarbital prior to cervical dislocation . Carbon dioxide and halothane 
overexposure were compared as well. The results of their experiment 
indicate that the type of euthanasia employed can significantly alter these 
immune parameters. Both methoxyflurane anesthesia and pentobarbital 
anesthesia prior to cervical dislocation significantly increased the 
lymphocyte proliferative responses . Pentobarbital anesthesia as well as 
C0 2 and halothane overexposure significantly decreased lympholysis (32) . 
Preparation of Drugs. Amphotericin B (Fungizone Intravenous; E. R. 
Squibb & Sons, Inc., Princeton, New Jersey) was reconstituted by rapidly 
injecting 10 ml Sterile Water for Injection USP (Abbott), without a 
bacteriostatic agent, directly into the vial. A 20 gauge needle was used . 
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This stock solution was vortexed until clear and was diluted to the 
appropriate concentrations with 5% Dextrose Injection USP which had 
0 .2% buffer added to adjust the pH to a physiological range . Buffer was 
prepared by adding 1.59 grams dibasic sodium phosphate (anhydrous) and 
0 .96 grams monobasic sodium phosphate (anhydrous) to a volumetric flask 
and filling to 100.0 ml with Sterile Water for Injection USP. The buffer was 
heat sterilized by autoclaving . Dilutions were made by adding 2.56, 1.28, 
0 .64, 0.32, 0 .16 and 0.08 milliliters of the amphotericin B stock solution 
to volumetric flasks and filling to 100 ml with 5% Dextrose to yield final 
concentrat ions of 128, 64, 32 , 16, 8 and 4 micrograms per milliliter, 
respectively . These represented 8x drug dilutions for final concentrations 
of 16, 8, 4 , 2, 1, and 0 .5 J,lg/ml in the actual experimental wells. All 
dilutions were refrigerated and protected from light . 
The liposomal amphotericin B (AmBisome; Vestar, Inc ., San Dimas, 
California) was prepared by rehydrating the drug with 12 ml of refrigerated 
Sterile Water for Injection USP. The exact lipid composition of this 
compound is proprietary. The vial was agitated for one to two minutes 
until the suspension was completely dispensed . Following agitation, the 
vial was incubated in a water bath for 10 minutes at 65 • C after which it 
was cooled to room temperature. This stock solution was diluted by 
aliquotting 3.2, 1.6, 0.8, 0.4, 0 .2 and 0 .1 ml of the liposomal amphotericin 
68 
B stock solution and filling the volumetric flasks to 100 ml with 5% 
Dextrose for Injection USP. This yielded 8x drug concentrations for final 
well concentrations of 16, 8, 4, 2, 1 and 0.5 pg/ml respective ly . 
Preparation of Splenocytes. Following in vivo administration of 
immune suppressive drugs, animals were euthanized and spleens were 
removed aseptically and placed into sterile, 15 ml polypropylene centrifuge 
tubes (Corning Glass Works, Corning, New York) containing 10 ml, pre-
warmed RPMI-PS which consisted of 99% RPMI-1640 (GIBCO BRL, Grand 
Island , New York) and 1% Penicillin-Streptomycin (GIBCO) . Due to the 
differences in splenic mass following immune suppression, five spleens 
were normally placed into each tube for the cyclophosphamide treated mice 
and three spleens for the immune normal and cyclosporine treated mice . 
The spleens and RPMI-PS from each centrifuge tube were poured 
into sterile, regular size lab bags (Tekmar Company, Cincinnati, Ohio). Air 
was removed from each bag prior to closing the top. Two bags were 
simultaneously placed into a stomacher tissue homogenizer (Lab-Blender 
80; Tekmar) and homogenized for exactly one minute . If the suspension 
was not adequately homogenous, the remaining portions of spleen were 
very carefully pressed out using a rubber print roller. The splenocyte 
suspension was poured off into its original centrifuge tube and any 
connective tissue debris which did not remain in the bag was removed 
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using a sterilized, wooden applicator stick. 
The tubes were centrifuged for five minutes at 200 x G. The 
supernatant was poured off . Nine milliliters of sterile, distilled water were 
then immediately added to the tube and the pellet was broken up by 
vortexing at low to medium speed. Within five seconds of adding the 
distilled water, 1 ml of 1 Ox phosphate buffered saline with pH between 7 .2 
and 7 .6 was added and the mixture was vortexed again . Any debris was 
again removed with an applicator stick . 
The tubes were again centrifuged for five minutes at 200 x G after 
which the supernatant was poured off. The pelleted cells were 
resuspended in 10 ml RPM I-PS and vortexed at low to medium speed after 
which any debris was aseptically removed . The tubes were centrifuged for 
five minutes at 200 x G after which the supernatant was poured off and 
the pellets resuspended in 5-10 ml media with 40% FBS. Media consisted 
of 1% 5mM 2-mercaptoethanol (Sigma). 1% sodium pyruvate (GIBCO), 1% 
penicillin-streptomycin, the amount indicated by percent of heat inactivated 
fetal bovine serum (FBS: Hyclone Laboratories, Logan, Utah) which was 
added shortly prior to use and the remaining portion consisting of RPMI-
1640. Heat inactivation included thawing and then incubating the FBS for 
30 minutes with the contents at 56· C and agitating every 10 minutes. 
The 2-mercaptoethanol acts as a macrophage stimulant in vitro for murine 
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cells . It is necessary to stimulate the T-cell response because murine 
macrophages are too few to respond without this stimulation . Sodium 
pyruvate was added to provide essential energy requirements of the cells . 
The fetal bovine serum was included to provide the growth factors 
necessary for cellular division and the penicillin -streptomycin was used to 
inhibit bacter ial growth from any possible contamination . 
Cells from each immune model were pooled in a sterile glass bottle. 
The three pooled samples were counted using Trypan Blue exclusion by 
adding 100 JJI of splenocytes to 900 JJI of Try pan Blue (EM Science , 
Gibbstown, New Jersey) and vortexing . Of this mixture , 10 JJI was placed 
on a hemacytometer and the live cells (those which did not take up the 
trypan blue ) were counted. Each bottle was diluted to 1 x 107 cells/ml with 
media containing 40% FBS . These served as the stock splenocyte 
suspensions . 
Viability Studies . The viability of the sp/enocytes was ascertained 
for immune normal cells by adding 100 JJI of the stock cell suspension to 
the wells of a 96 well, round bottom, tissue culture plate (Corning) to 
which 75 JJI and 100 JJ/ of media with no FBS had already been added for 
test wells and for the control wells respectively . Lastly, 25 JJI of 8x 
concentrations of amphotericin B or liposomal amphotericin B was added 
to the appropriate wells in sexteplicate . The plate was then incubated for 
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24 hours at 37" C in 5% C0 2 • At the end of the incubation, the 
conce ntration of cells in each well was determined using a Coulter Counter 
(Coulter Electronics , Inc., Hialeah, Florida) . This was accomplished by 
adding 10 ml counting fluid (Isotone II; Coulter) into separate blood dilution 
vials (Coulter). Two drops of lysing fluid (Lysing and Hemoglobin Reagent, 
Manual; American Scientific Products , McGaw Park, Illinois) were placed 
into each vial following which 10 pi of the cells from the test wells were 
added. Each vial was then inverted a couple of times before counting. The 
cell counts were converted to a percentage by taking the ratio of the 
original concentration (5 x 106 cells/ml). 
Lymphocyte Proliferation Studies . Lymphocyte proliferation was 
determined using Lipopolysaccharide (LPS; Sigma) for the 8-cell mitogen 
and Concanavalin A (Con A ; Sigma) for the T-cell mitogen . The LPS was 
rehydrated using sterile RPMI-1640 and diluted with the same to 40 pg/ml 
and 20 pg/ml. The Con A was also suspended in RPMI-1640 into 5 pg/ml 
and 2.5 pg/ml concentrations. One-hundred microliters of the appropriate 
mitogen were placed into both the test wells and the six immune normal 
control wells of a 96 well, flat bottom, tissue culture plate (Corning). 
Twenty-five microliters of media with no FBS were added to these wells. 
One-hundred and fifty microliters of the same media were placed into the 
background control wells . Fifty microliters of stock splenocytes were 
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added to all wells after which 25 JJI of 8x concentrated dilutions of 
amphotericin B or liposomal amphotericin B was added to the appropriate 
test wells. This produced final LPS concentrations of 20 Jlg/ml and 10 
JJg /ml and Con A concentrations of 2 .5 JJg /ml and 1.25 JJg /ml respectively . 
The final splenocyte concentration was 5 x 106 cells/ml in a 10% FBS 
solution . Plates were then incubated for 24 hours at 37 " C in 5% C02 • 
After 24 hours, cells were pulsed with 2.0 JJI (0.4 mCi /mMol) methyi-
3H-thymidine (Dupont NEN Products, Boston , Massachusetts) and incubated 
for an addit ional 24 hours under the same conditions. Cells were harvested 
on standard, self-aligning glass fiber filters (Packard Instrument Company, 
Meriden, Connecticut) using a Packard Microplate 1 96 Well Harvester 
(Packard) by aspirating the cells through the filter and washing the cells 
four additional times . The filters were then dried for 24 hours at room 
temperature or for one hour at 60 • C. Filters were read for 1 0 minutes 
using a Matrix 96 Well Direct Beta Counter (Packard) and the data was 
expressed as counts per minute (CPM). 
Macrophage Function Studies by lnterleukin-1 (11-1) Production. 
Macrophages were incubated in Falcon 24 well , flat bottom tissue culture 
plates (Becton Dickinson Labware, Lincoln Park, New Jersey) by pipetting 
0.75 ml of 0% Mouse Media into each well and adding 0 .25 ml stock 
splenocyte solution. The plate was incubated for one hour at 37" C in 5% 
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C0 2 in order to allow the macrophages to adhere to the well surfaces . At 
the end of the hour incubation , the non-adherent cells were removed by 
inverting the plate over the sink and gently washing each well with 0 .2 ml 
of med ia with 10% FBS which was also discarded. Each test well then 
received 1.75 ml 11-1 media with 5% FBS and 2% LPS (1 mg/ml and 
reconstituted with RPMI-1640) for a final LPS concentration of 20 )Jg /ml. 
Control wells received 1. 75 ml of 11-1 control media which was media with 
5% FBS and no LPS. All wells then received 0.25 ml of 8x concentrated 
drug dilutions for a final volume of 2 mi. The plates were incubated for 24 
hours at 37" C and in 5% C0 2 • Following incubation, the supernatants 
were pipetted off and placed into lidless 5 ml culture tubes (American 
Scientific Products) and centrifuged for 10 minutes at 300 x G to remove 
all cells. Each tube was then poured into a new tube which was frozen for 
storage. 
At the time of testing, 100 JJI of undiluted as well as 1:2 diluted 
supernatant (diluted with 5% Mouse Media) were pipetted into the wells 
of a 96-well, flat bottom tissue culture plate. Mouse thymocytes were then 
prepared by aseptically removing the thymuses from three week old BALB/c 
mice (Simonsen) and placing them into sterile, 15 ml centrifuge tubes 
containing 10 ml, pre-warmed RPM I-PS. Two thymuses were placed into 
each centrifuge tube . The thymuses from each centrifuge tube were 
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poured into sterile, regular size lab bags along with the 10 ml RPMI-PS . 
The air was removed from each bag prior to closing the cap. Two bags at 
a time were placed into a stomacher and stomached for 50 seconds. The 
thymocyte suspension was poured back into its original centrifuge tube and 
any connective tissue debris which was not contained in the bag was 
removed using a sterilized , wooden applicator stick . 
The thymocytes were centrifuged for five minutes at 200 x G, the 
supernatant was poured off, and which the pellets were resuspended in 10 
ml RPMI-PS and vortexed at low to medium speed . The cells were again 
centrifuged for five minutes at 200 x G, the supernatant was poured off 
and the pellets were resuspended in 10 ml of 11 -1 thymocyte media which 
consisted of 20% FBS and 4% phytohemagglutinin stock solu t ion (PHA; 
GIBCO) which was added immediately prior to addition of thymocytes to 
the wells . The thymocytes were pooled and counted on a hemacytometer 
using trypan blue exclusion and diluted to 1. 5 x 10 7 cells/ml with 11-1 
Thymocyte Media . 
The thymocytes, in 100 pi aliquots, were added to all wells of the 
96-well plates containing the supernatants. The cells were incubated for 
48 hours at 37" C in 5% C0 2, and pulsed with 2 pi (6.7 Mci /Mmol) of 
methyi-3H-thymidine and incubated for an additional 24 hours. Cells were 
harvested on glass fiber filters using a Packard Microplate 196 Well 
75 
Harvester by aspirating the cells through the filters and washing the cells 
four additional times . The filters were dried for one hour at 60 • C and 
radioactivity in the filters counted for 10 minutes using a Packard Matrix 96 
Well Direct Beta Counter and the data was expressed as CPM . 
Data Analysis and Statistical Methods Used . Each 96-well 
microplate represented one immune model's experimental unit and 
contained all drug dilutions for both amphotericin B and liposomal 
amphotericin B as well as immune normal control wells for both the viability 
and the lymphocyte proliferation studies. Background control wells were 
also included on each microplate for the lymphocyte proliferation studies . 
All drug dilutions, immune normal controls and background controls were 
replicated in six different wells . The background counts are listed, along 
with all other raw data, in the tables found in the appendices . The mean 
of the immune normal control wells was used to help visually standardize 
the other experimental values by a single dotted line on each graph 
representing that value . Using this value as a reference allows the 
determination of the relative amount of stimulation or inhibition of immune 
functions by the two drugs under examination. The immune normal control 
wells received no immunosuppression, no drug and no drug carrier. These 
wells did receive the appropriate amount of mitogen. The values from the 
different experimental replications were pooled, averaged and graphed . 
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Using Minitab software, the analysis of variance was performed for 
each immune model and for each mitogen level or dilution of interleukin-1 
supernatant in the lymphocyte proliferation and macrophage activation 
assays , respectively. Specifically, the experimental values were compared 
between amphotericin B and liposomal amphotericin B, between the 
different doses used as well as between the different replications of the 
experiments which were run on different days . 
The results of the viability stud ies were determined by calculating the 
percent of viable cells as compared to the original number of cells per well . 
In the lymphocyte proliferation studies, the background counts were not 
subtracted from the experimental values but are reported in tables 
(appendices) to demonstrate that they were well within acceptable limits 
of proper experimental procedures. The background counts were 
subtracted from the experimental values in the macrophage activation 
studies since each set of experimental values had its own set of 
background values . 
The standard error of the mean was used to graphically represent the 
deviations of each experimental value from each separate experimental unit 
with no discrimination between the individual experiments such that all 
values had equal weighting. 
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RESULTS 
Model Validation and Standardization. Figure 7 represents results 
obtained in order to optimize the concentration of LPS as a mitogen for the 
8-lymphocyte proliferation studies. This particular study was also 
conducted to optimize the concentration of splenocytes which were chosen 
for both the 8- and T-lymphocyte proliferation studies. This study was only 
conducted with splenocytes from immune normal mice . Both 10 JJg/ml and 
20 JJg /m l of LPS were chosen because these concentrations represented a 
level plateau in the stimulatory effect on 8-cells. The higher cell 
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FIGURE 7 . Effect of different LPS concentrations on 3H-Thymidine uptake 









concentration was chosen as well due to the marked increase in uptake of 
3H-Thymidine. The counts when using 1 x 106 cells /ml were relatively low 
whereas those when using 5 x 106 cells/ml were in a more acceptable 
range . Cell proliferation was measured by determining the amount of 
radioactive 3H-thymidine which was incorporated into the DNA of dividing 
cells. Th is was done with a scintillation counter and was enumerated as 
counts per minute (CPM). 
Another important parameter to measure was the amount of drug 
vehicle , 5% Dextrose, USP, which could be used without affecting the 
results of the various studies . Figure 8 represents the effects of various 
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FIGURE 8. Effect of different concentrations of 5% Dextrose, USP on the 





concentrations of 5% dextrose on cellular viability . It was determined to 
use a 12.5% concentration of the 5% dextrose solution because its effects 
on the viability of cells did not exceed the viability of cells which received 
no drug carrier. It was also chosen because it would be a convenient 
volume to use in the experimental wells of the various studies . This 
concentration would represent a volume of 25 Jil out of the 200 JJI total 
volume added to each well of a 96-well microplate. A smaller amount than 
this would be difficult to measure. This would require 8x drug 
concentrations to be contained within the 25 Jil doses . 
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FIGURE 9 . Effect of different concentrations of 5% Dextrose, USP on 3 H-






The results of different concentrations of 5% dextrose on LPS 
induced B-cells also confirms the decision to use the dextrose at 12.5%. 
Note in Figure 9 that at this concentration there appears to be no 
stimulation of the B-cells. There may even be some inhibition of B-cell 
functions but this was ignored for the positive indications noted in the other 
studies at this concentration. Both concentrations of LPS demonstrated 
very similar results . 
Figure 10 shows that the effects of a 12.5% concentration of 5% 
dextrose on the T-ce ll population is nominal. Up to this concentration , 
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FIGURE 10. Effect of different concentrations of 5% Dextrose, USP on 3 H-
Thymidine uptake by T-lymphocytes using 2.5 pg/ml and 1.25 pg/m l Con 
A as mitogen. 
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lymphocytes stimulated with Con A . Above this concentration, there is a 
slight increase in activity up to 20% dextrose and above this point there is 
a much steeper increase in stimulation . The effects of both mitogen 
concentrat ions in this study were quite homogenous . 
Viability Studies. Immune normal splenocytes. The viability studies 
were conducted only on splenocytes from immune normal animals. The 
results illustrated by Figure 11 are a composite of data from three separate 
experiments . The significance of the various parameters of the experiment 
as determined by the analysis of variance is listed in Table 1 c . 
The results show that the difference between amphotericin B (AmB) 
and liposomal amphotericin B (L-AmB) is significant (p < 0.001 ). Closer 
scrutiny of the graph, however, reveals that the differences are actually 
relatively small. Amphotericin B was consistently more toxic but not to any 
substantial degree. The greatest difference was at a drug concentration of 
8 pg/ml where there is approximately a 10% difference between the two 
drugs. This difference is not of extreme importance because this 
concentration exceeds the achievable peak plasma concentrations for 
amphotericin B. In the lower drug ranges, representing more realistic 
plasma concentrations for amphotericin B, the differences are closer to 5%. 
The differences between the doses were significant (p < 0 .001) but 
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FIGURE 11 . Effect of amphotericin B and liposomal amphoteric in B on the 
viability of immune normal splenocytes. 
inhibition of any importance . This finding is especially important for 
liposomal amphotericin B because the higher doses used are achievable in 
vivo without the same reported side effects of renal toxicity as is found 
with the free form of the drug . 
By referring back to Figure 8, it is apparent that liposomal 
amphotericin B, of itself, is not toxic. The "toxicity" which is demonstrated 
by an 80% viability for cells treated with the liposomal preparation is no 
different than the toxicity exhibited by the drug vehicle at the 12.5% 
concentration as illustrated in Figure 8 . This effect. therefore, is either due 
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to the drug vehicle or to the technique employed rather than to liposomal 
amphotericin B. This effect is probably due to the technique because it is 
not too dissimilar from results illustrated in Figure 8 when no drug vehicle 
was used. Since the results illustrated in Figure 11 obtained from cells 
exposed to amphotericin B are "significantly" lower than those for the 
liposomal preparation or for the drug carrier , this indicates that th is form of 
the drug is probably slightly toxic. 
8-Cell Proliferation Studies . Immune normal splenocytes. The results 
for this study , represented in Figure 12, are a composite of data from three 
separate experiments. The p-values from the different aspects of the 
analysis of variance are presented in Table 2c and Table 3c . The 
differences between the two drugs in both sets of experiments, which 
represent two concentrations of LPS, were significant (p < 0 .001 ). The 
differences between the drug concentrations used in both sets of 
experiments were significant as well (p < 0.001 ). 
Over a broad spectrum of drug concentrations utilized, amphotericin 
B demonstrated a high amount of toxicity to B-cell activity. This mainly 
occurred, however, towards the higher concentrations which exceed 
clinically re levant plasma concentrations between 0 .5 - 2 pg/ml for 
amphotericin B. At these normal therapeutic levels of the drug, there were 
basically no important concentration effects noted other than the fact that 
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FIGURE 12. Effect of amphotericin B and liposomal amphotericin B on 3H-
Thymidine uptake by immune normal B-lymphocytes using 20 J)g/ml and 10 
J)g/ml LPS as the mitogen . 
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its effect may have been only slightly toxic in comparison to the immune 
normal control cells. 
Liposomal amphotericin B does not appear to have any notable 
toxicity in comparison to amphotericin B. Its effects basically remain 
adjunct to the immune normal control cells up through 8 JJg /ml, indicating 
neither stimulation nor inhibition. Following this concentration , however, 
the activity of the 8-cells increases above this level at the higher mitogen 
concentration and deviates slightly below this level at the lower mitogen 
levels . Once again, because liposomal amphotericin B is able to be used 
therapeutically at these higher levels, an important asset when fighting 
mycotic infections, its lack of toxicity to B-cells could be of extreme clinical 
importance . 
Cyclosporine compromised splenocytes. The results from both sets 
of experiments conducted at different mitogen levels, as illustrated in Figure 
13, are a composite of data from three separate experiments. The results 
of the analysis of variance are presented in Table 4c and Table 5c. In both 
cases, the differences between amphotericin Band liposomal amphotericin 
8 as well as the differences between the different concentrations utilized 
were significant (p < 0 .001 for both mitogen levels). 
As with the immune normal splenocytes, amphotericin 8 was highly 
toxic at the higher drug concentrations . Its toxic effects were not as 
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FIGURE 13. Effect of amphotericin B and liposomal amphoteric in B on 3 H-
Thymidine uptake by cyclosporine compromised B-lymphocytes using 20 
tJg /ml and 10 tJg /ml LPS as the mitogen . 
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pronounced at the lower therapeutic levels between 0.5- 2 JJg/ml although 
a significant decrease in activity occurred in both experiments immediately 
at 0 . 5 JJg /ml. 
The effects of liposomal amphotericin 8 were again nominal in that 
over most of the concentration range, there seemed to be no profound 
stimulation or inhibition . Beyond 8 Jlg /ml at both mitogen levels , however, 
there was an apparent increase in activity suggestive of immune 
stimulation . In the cyclosporine compromised patient, this could be of 
clinical importance because when using liposomal amphotericin 8, higher 
antifungal concentrations can apparently be achieved without further 
compromising 8-cell mediated immunity. This arm of the immune system 
may in fact be stimulated at concentrations exceeding 8 Jig /mi. 
The data for both drugs at the higher mitogen concentration 
consistently remained below the immune normal control splenocytes. At 
the lower levels of LPS, however, the results for both drugs were closer to 
this level with liposomal amphotericin 8 maintaining a slightly higher level 
throughout the different dose levels. 
Cyclophosphamide compromised splenocytes. The results shown in 
Figure 14 are representative of three separate experiments. The results 
from the analysis of variance are listed in Table 6c and Table 7c . At the 
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FIGURE 14. Effect of amphotericin B and liposomal amphotericin B on 3H-
Thymidine uptake by cyclophosphamide compromised B-lymphocytes using 
20 JJg /ml and 10 JJg /ml LPS as the mitogen. 
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drugs . As can easily be seen, the only real deviation occurred beginning at 
4 pg /ml. This could be due to the extreme immunosuppressive status of 
the splenocytes resulting from the cyclophosphamide treatment of these 
animals . Although the difference between the drugs at the lower mitogen 
level were significant (p < 0.001 ), this deviation occurred at drug 
concentrations exceeding the achievable therapeutic levels for amphotericin 
B. In both cases, amphotericin B was eventually toxic to the cells, 
whereas, the effects of liposomal amphotericin B did not demonstrate either 
stimulation or further inhibition . This, once again, could be of clinical 
importance because it would allow higher clinical levels of the drug to be 
achieved in immune compromised individuals suffering from fungal 
infections without creating further immunosuppression of whatever remains 
of their humoral immunity. At both levels of mitogen, the differences 
between the separate drug concentrations was significant (p < 0.001 for 
both mitogen levels). 
T -Cell Proliferation Studies. Immune normal splenocyte. The results 
illustrated by Figure 15 are the combination of four separate experiments . 
The results of the analysis of variance for this study are presented in Table 
8c and Table 9c. At both levels of Con A, the differences between the two 
drugs as well as between the different drug concentrations were significant 
(p < 0.001 for both parameters at both mitogen levels). In both cases, 
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FIGURE 15. Effect of amphotericin 8 and liposomal amphotericin 8 on ' H-
Thymidine uptake by immune normal T-lymphocytes using 2 .5 JJg /ml and 
1.25 JJg /ml Con A as the mitogen . 
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amphotericin B was again highly toxic once clinical therapeutic levels of 0.5 
- 2 pg/ml were exceeded . Up through 4 pg/ml of the drugs, amphotericin 
B basically had no effect on this T-cell population but thereafter was 
severely toxic . 
On the other hand , liposomal amphotericin B did not have any 
notable effect upon T-cell activity . There was a noted increase in T-cell 
activity with liposomal amphotericin B beyond 8 pg/ml at both mitogen 
concentrations suggesting the possibility of the drug stimulating these cells . 
At the lower concentration of Con A , liposomal amphotericin B caused a 
slight initial decrease in activity but the effects of the liposomal drug were 
otherwise quite stable . At this mitogen concentration, there was also a 
decrease from the immune normal control value but as the drug 
concentration was increased to 16 pg/ml, this value was regained . 
Cyclosporine compromised splenocytes. The results represented by 
Figure 16 are the mean figures for four separate experiments. The results 
of the analysis of variance conducted on this splenocyte population are 
presented in Table 1 Oc and Table 11 c. The overall level ofT-cell activity 
was depressed due to the immunosuppressive administration of 
cyclosporine. At both concentrations of Con A, the differences between 
both drugs as well as the doses used were significant (p < 0 .001 for both 
parameters at both mitogen levels) . In this immune model, the toxic effects 
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FIGURE 16. Effect of amphotericin Band liposomal amphotericin Bon 3H-
Thymidine uptake by cyclosporine compromised T-lymphocytes using 2 .5 
JJg /ml and 1.25 JJg/ml Con A as the mitogen . 
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of amphotericin B against the T-cell response was again demonstrated at 
the higher concentrations . The toxicity was apparent beginning at 2 pg /ml, 
however, in comparison to the immune normal model where toxicity was 
first noted at 4 pg/ml. There was also a small initial drop in activity at 0.5 
pg/ml for cells exposed to amphotericin B but once reached , this value 
remained relatively constant until 2 pg/ml after which point severe 
immunosuppression was again noted. 
Liposomal amphotericin B again had no appreciable effect on the T-
cell response indicating neither stimulation or toxicity . All values were 
somewhat below the immune normal control values which, as mentioned 
above, would be expected from cyclosporine's immunosuppressive effects, 
especially against T-helper cells . Beyond 8 pg/ml , however, the liposomal 
drug increased the activity of the T-cell population somewhat indicating the 
possibility of immune stimulation. 
The differences between the two drugs could indicate important 
clinical implications for the treatment of organ transplant patients who are 
battling fungal complications . Although at therapeutic levels amphotericin 
B may not be significantly toxic to the already immunosuppressed T-cells, 
much higher levels of the drug are achievable in the liposomal preparation 
without any in vitro T-cell toxicity . 
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Cyclophosphamide compromised splenocytes. The results presented 
in Figure 17 represent data from three separate experiments . Results from 
the analysis of variance are presented in Table 12c and Table 13c. 
Immunosuppression of splenocytes by administration of cyclophosphamide 
greatly reduced the ability of T-cells to respond in comparison to the 
immune normal control cells . At the higher concentration of Con A, there 
was no significance demonstrated between the two drugs . The differences 
between the drugs at the lower mitogen concentration , however, was 
significant (p < 0 .001 ). The differences between the individual doses at 
both mitogen concentrations were also significant (p < 0.001 ). 
In either of the graphs , there was no real deviation between the 
drugs until 8 pg/ml had been exceeded . At this point, amphotericin B was 
again severely toxic whereas liposomal amphotericin B slightly increased T-
lymphocyte activity. It appeared that at lower drug concentrations, both 
amphotericin B as well as liposomal amphotericin B may actually have 
stimulated the T-cells . This dropped off, however, with both drugs once 
4 pg/ml had been reached . The drop-off continued beyond this point in the 
case of amphotericin B but was slightly elevated again with liposomal 
amphotericin B following 8 pg/ml. 
The clinical potential could be interpreted as two different 
possibilities. It appears that amphotericin B, when used at achievable 
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FIGURE 17. Effect of amphotericin Band liposomal amphoteric in Bon 3 H-
Thymidine uptake by cyclophosphamide compromised T-lymphocytes using 
2 .5 ,ug/ml and 1.25 ,ug/ml Con A as the mitogen . 
96 
therapeutic doses may be as safe as liposomal amphotericin B when the 
latter is used at higher therapeutic dose levels. Once again, however, it 
appears that the use of liposomal amphotericin B may allow more drug to 
be delivered to an infected person without the same toxic effects . 
Macrophage Activation . The counts per minute produced by this 
assay were quite low. Thymocytes were induced to proliferate by the 
addition of the macrophage induced 11-1 from macrophages presented with 
amphoter ic in B and liposomal amphotericin B at different concentrations. 
The data is presented with this explanation because though low, the values 
appear consistent with each other as well as with the above described 
results for B- and T-lymphocyte responses. 
Immune normal splenocytes. The results illustrated by Figure 18 
represent data from three experiments. The results from the analysis of 
variance are presented in Table 14c and Table 15c. The study where in 
thymocytes were stimulated with undiluted supernatant containing the 
macrophage produced 11-1 demonstrated significant differences between 
both amphotericin B and liposomal amphotericin B as well as between the 
doses utilized (p < 0 .001 ). In the 1:2 diluted samples, the difference 
between the drugs was significant (p < 0.001) whereas there was no 
significance demonstrated between the doses . 
In both instances, amphotericin B appeared to be highly toxic to the 
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FIGURE 18. Effect of amphotericin B and liposomal amphotericin B on 
immune normal macrophages as measured by 3H-Thymidine uptake by 
thymocytes stimulated by und iluted and 1 :2 diluted supernatant containing 
t he lnterleukin- 1 produced by the macrophages . 
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macrophages. In the 1 :2 diluted sample, this was not apparent until 4 
,ug/ml whereas in the undiluted samples, the toxicity was apparent 
following 1 ,ug/ml. All values representing macrophages exposed to 
amphotericin B were below the values for the immune normal control cells. 
On the other hand , the effect on cells exposed to liposomal 
amphotericin B either remained adjunct to the immune normal control 
values or was actually above this point suggestive of stimulation. In the 
undiluted samples, the results of liposomal amphotericin B exposure did not 
change remarkedly but did remain slightly above the immune normal control 
value . In the 1:2 diluted sample, however, the activity from macrophages 
stimulated with liposomal amphotericin B rose above the immune normal 
control val ue following 1 ,ug/ml of drug and remained above until the results 
finally flattened out between 8 and 16 ,ug/ml. This is highly suggestive of 
immune stimulation of this macrophage population by the liposomal 
preparation . 
Cyclosporine compromised splenocytes. The results indicated by 
Figure 19 represent data collected from two separate experiments. The 
results from the analysis of variance are presented in Table 16c and Table 
17c. In both the undiluted and 1:2 diluted samples, the differences 
between the drugs and the doses were significance (p < 0 .001 for both 
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FIGURE 19. Effect of amphotericin B and liposomal amphotericin B on 
cyclosporine compromised macrophages as measured by 3H-Thymidine 
uptake by thymocytes stimulated by undiluted and 1:2 diluted supernatant 
containing the lnterleukin-1 produced by the macrophages. 
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were also significant (p < 0 .001 for undiluted and p < 0 .05 for 1 :2 diluted 
supernatants) . 
In both cases, amphotericin B was again highly toxic. In the 1:2 
diluted sample this became apparent following 1 JJg /ml of drug but was 
obvious in the undiluted sample immediately upon the addition of 
amphotericin B. In the undiluted sample, liposomal amphoteric in B 
appeared to have a stimulatory effect which leveled off following 2 JJg /ml 
but remained well above the immune normal control line . The immune 
normal control value , however, seemed questionable in this example . The 
1:2 diluted data indicated stimulation with liposomal amphotericin B 
exposure but was not nearly as apparent as in the undiluted samples . Once 
again, it appeared that liposomal amphotericin B may have some important 
clinical advantages over amphotericin B because higher concentrations are 
achievable without the same apparent signs of immunotoxicity. 
Cyclophosphamide compromised splenocytes. The results illustrated 
by Figure 20 represent data grouped from two experiments. The results 
from the analysis of variance conducted on this study are listed in Table 
18c and Table 19c. In the undiluted samples, the differences between the 
drugs was significant (p < 0.05) but there was no significance between 
the doses. There was no significance demonstrated between the drugs or 
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FIGURE 20. Effect of amphotericin B and liposomal amphotericin B on 
cyclophosphamide compromised macrophages as measured by 3H-
Thymidine uptake by thymocytes stimulated by undiluted and 1 :2 diluted 
supernatant containing the lnterleukin-1 produced by the macrophages . 
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The same apparent effect seemed to be evident in both samples. 
Amphotericin 8 appeared to be toxic to the cells following 1 .ug/ml. 
Liposomal amphotericin 8 appeared to possess immunostimulatory 
characteristics in both instances by raising the production of 11-1 to the 
levels achieved by the immune normal control cells. Again this could have 
important clinical implications from the standpoint that higher 
concentrations of the antifungal drug could be achieved in a patient without 
further immune compromising his already weakened immune status. It 
even appears that at the higher doses of liposomal amphotericin 8, an 
immune compromised patient's immune status may actually be stimulated 
by the use of the drug . 
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DISCUSSION 
A normal, immune competent individual is relatively risk free from 
serious fungal infections. Recent years, however, have witnessed the 
increase of different factors which predispose patients to severe mycotic 
insult due to a depression of their immune status. Organ transplant 
patients receiving cyclosporine, individuals undergoing cancer 
chemotherapy with drugs such as cyclophosphamide and the recent 
outbreak of the AIDS epidemic have all been players upon the ever growing 
stage of fungal, opportunistic diseases . Though good antifungal 
preparations have been available for more than 30 years , they are only 
useful within a very narrow therapeutic index and the attending physician 
must carefully weigh the seriousness of the fungal infection versus 
complications associated with drug toxicity. 
Amphotericin 8 has long been the drug of choice in serious, life-
threatening mycoses which are generally either limited to a specific organ 
or of a systemic nature. The drug is successful because it is fungicidal 
rather than fungistatic as is the case for most other antifungal compounds. 
Its toxicity to the renal system has been the complicating factor which 
physicians have been forced to deal with . One method recently discovered 
in which the full antifungal qualities of the drug have apparently been 
maintained while the toxic effects have been sharply reduced has been to 
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formulate nanometer sized particles of the free drug into liposomal vesicles . 
This is the basis for the formulation of liposomal amphotericin B. 
Immunologically, both amphotericin B as well as liposomal 
amphotericin B have been characterized as immunostimulants. Authors 
suggesting this characteristic have tested the drugs using various 
parameters both in vivo and in vitro . The results of this study, which are 
representative of results obtained in vitro certainly do not support the 
notion that amphotericin B is an immunostimulant . The immunosuppressive 
effects of amphotericin Bon splenocytes from immune normal, cyclosporine 
compromised and cyclophosphamide compromised splenocytes exposed to 
20 and 10 Jlg /ml LPS for stimulation of B-cells and T-cells which were 
stimulated using 2.5 and 1.25 JJg /ml of Con A cannot support the 1977 
report by Blanke et al. who concluded that amphotericin B augmented both 
humoral as well as cell-mediated immunity. Their results were obtained in 
vivo ( 12) . In each instance, the results of the current study indicated that 
exposure to amphotericin B in excess of 2 to 4 JJg /ml resulted in severe 
suppression of these two cell populations . T-cells from cyclophosphamide 
compromised mice may be the only possible exception to the total lack of 
immunostimulation by amphotericin B, however, the effect was very weak 
and was not likely biologically relevant . 
Vecchiarelli et al. reported in 1986 that the stimulatory effects were 
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activation rather than proliferation and if this is actually the case, the 
assays performed in the studies reported here can neither support nor reject 
Vecchiarelli's theory for lymphocytes since cell proliferation was the 
response measured. Macrophage activation , however, was determined by 
their activation to produce 11 - 1 and again there was no stimulation noted to 
support Vecchiare lli ' s findings which were obtained in vivo (69 ). 
The 1985 report by Mehta et al. concerning the in vitro activation of 
monocytes and suppressor T-cells by amphotericin B is also not supported 
by the current study (49) . There was no apparent activation of the general 
T-cell population nor was there any activation of macro phages by exposure 
to amphotericin Bas determined by the amount of 11-1 produced . 
It is of interest to note the concentration range where splenocytes 
exposed to amphotericin B demonstrate such a notable toxic response. 
Almost without exception, this occurs at concentrations above clinically 
relevant drug doses of 0 .5 to 2 tJg /ml. The general lack of toxicity to the 
immunological cells in this range is, of course, very similar to the range 
where toxicity to other tissues, such as the kidneys, is at least tolerated. 
This might indicate that drug toxicity with amphotericin B is due to similar 
parameters for mammalian cells in general. 
Considering liposomal amphotericin B, however, the results of this 
study do show that this drug does not cause the same, severe toxic effects 
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that were demonstrated by exposure to amphotericin 8 when its clinically 
relevant concentrations had been exceeded. Values for cells exposed to 
this liposomal formulation were relatively constant throughout the 
experiment demonstrating only slight variations in activity over the 
spectrum of concentrations utilized. For the drug concentrations used in 
the B- and T-cell studies, liposomal amphotericin 8 did not significantly alter 
the ability of lymphocytes to respond to the appropriate mitogen . There 
was even some apparent stimulation of both the 8- and T-cell populations 
which received drug concentrations greater than 8 vg /ml. This was true for 
both immune normal and immune compromised splenocytes . Stimulation 
was also apparent in the macrophage studies but due to fairly low overall 
counts, this can only be stated with reservation. 
As observed from the viability studies presented in this text, the 
viability of cells exposed to amphotericin 8 were as much as 1 0% less than 
those exposed to liposomal amphotericin B (around 70% viability for cells 
exposed to amphotericin B compared to about an 80% viability for cells 
exposed to liposomal amphotericin 8 as shown in Figure 11 ). It is 
suggested that even though liposomal amphotericin 8 showed a viability of 
80% (Figure 11 ), this was due to the methods utilized in this assay and not 
due to drug toxicity since values were very similar to values from studies 
measuring the viability of splenocytes which were not exposed to either 
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drug or drug carrier (Figure 8). From these results, it would be expected 
that the theory of toxicity from amphotericin B due to the creation of ion 
pores is certainly a tractable possibility . The fact, however, that the effect 
of amphotericin B on splenocyte viability did not demonstrate the same 
toxic effects as were noted in the functional assays, even at the higher 
concentrations used , suggests that the drug may be highly toxic to the 
immune responsiveness of many of these cells without actually destroying 
them . In the case of lymphocytes , this would indicate an inhibition of 
cellular division . It would indicate an inhibition of 11-1 production by the 
macrophages. A possible explanation for this would be that although ion 
pores may be created in the cell membranes of immune cells, they are not 
large enough to actually cause cellular death . Rather they may simply 
cause the severe depletion of available stores of cellular ATP because the 
A TP-dependent Na + -K + pumps are forced into abnormally high activity in 
an attempt to restore and/or maintain normal ion gradients in spite of the 
pores which are created by the drug. This would deplete the cellular 
energy reserves and hence reduce their ability to proliferate since this is a 
very energy dependent process. Further investigation into the actual 
mechanism of toxicity to immune cells is warranted. 
The overall clinical potential of liposomal amphotericin B is quite high 
for several reasons. Results of this study show that even though 
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amphoteri cin 8 does not appear to be immunotoxic within clinically relevant 
concentrations , once these are exceeded, it becomes highly toxic . Drug 
concentration can be increased significantly, however, using the liposomal 
preparation without any apparent toxic effects to the immune cells . 
Reports by Mehta et al. have indicated that liposomal amphotericin 8 is also 
much less tox ic to the kidneys but retains the same antifungal level as the 
free drug preparation at similar concentrations (49). Under these conditions 
alone , liposomal amphotericin 8 shows great potential. The evidence cited 
in this study concerning liposomal amphotericin 8 ' s lack of toxicity to 
immune cells makes it even more favorable . Administering a drug, such as 
amphoteric in 8, which is immunosuppressive beyond a very narrow 
therapeutic index to a patient who is suffering from a fungal infection 
because of an already immune compromised status is all the more reason 
to consider the potential of a drug, such as liposomal amphotericin 8, 
which has equivalent fungicidal activity and can be administered at higher 
concentrations without further toxicity to the activity of the remaining 
immune cells. 
The immunological effects of each drug in immune-suppressed 
patients suffering from life-threatening fungal infections should be 
researched and evaluated for a clearer understanding of the in vivo effects . 
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TABLE 1a . Effects of amphotericin 8 on the viability of immune normal 
splenocytes expressed as the percent of viable cells compared 
to the original concentration following a 24 hour incubation . 
IMMUNE NORMAL VIABIIJTY 
FUNGIZONE 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 
12 82.56 60.68 57 .84 59.08 60.08 70.36 71.96 
76.20 61.16 67.76 65 .16 61.60 73.36 65.36 
65.08 62.68 61.08 76.36 55.64 71.20 66. 16 
74.16 54.76 56.88 60.28 63.76 74.32 86.44 
60.16 55.44 66.04 66.16 61.32 68.96 68.64 
59.16 68.56 49.96 64.20 58 .20 71.36 75.24 
13 71.32 79.44 55.56 78.60 67.88 77.88 88.04 
69.28 65.24 65.32 80.44 75.44 60.04 82.72 
61.24 69.80 55.48 85 .20 85.92 95.24 68.36 
64.68 60.16 79.16 108.92 71.60 73.92 78.64 
85.20 65.84 55.68 107.20 53.84 63.32 74.96 
74.24 52.96 80.04 74.68 75.28 67 .60 78.76 
14 85.52 88.52 84.40 80.48 98 .80 80.92 106.20 
71.28 85.40 83.48 95.88 76.00 72.80 90.44 
69.52 78.44 96.76 67.60 83.56 76.44 78.92 
74.56 69.68 85 .00 96.00 88.00 69.08 91.88 
72.96 85.16 95.96 86.16 96.80 81.60 104.04 
65.60 95.56 80.12 62.24 77.28 75.08 88 .00 
Mean 71.26 69.97 70.92 78.59 72.83 73.53 81.38 
S.E. 1.87 2.98 3.50 3.67 3.24 1.81 2.83 
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TABLE 1 b . Effects of liposomal amphotericin Bon the viability of immune 
normal splenocytes expressed as the percent of viable cells 
compared to the original concentration following a 24 hour 
incubation . 
IMMUNE NORMAL VIABILITY 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 
12 59.16 71.72 53 .60 61.72 68 .00 69.60 66.08 
67.36 58.56 62.60 65.36 62.60 67.36 71.68 
67.60 69.72 66.52 66.76 63.56 72.44 66.64 
56.28 63 .64 64.88 54.00 67.76 67.04 75 .24 
71.52 71.4 74.84 69.64 65.00 76.44 94.16 
75 .28 75.04 78.36 80.40 69.44 68.24 74.24 
13 87.32 78.64 71.48 66.88 75.52 78.00 69.72 
82.48 65.84 75 .92 102.48 82.12 102.40 74.04 
72.20 68.76 84.02 73 .16 77.68 85.00 81.16 
95.24 104.48 76.76 88.76 98.80 71.88 82.32 
73.20 73.64 90.28 103.16 94.00 70.64 80.56 
60.32 103.20 115.88 132.68 94.04 72.32 91.08 
14 94.82 89.60 79.76 84.76 83.60 88.56 86.20 
82.80 95.00 84.40 87.00 66.12 78.32 74.36 
83.08 81.08 85.20 81.36 80.96 75.80 97 .80 
64.44 95.12 85.20 84.44 74.88 97.52 102.68 
88.28 88.32 84.84 97.00 87.04 89.76 87.12 
82.16 79.76 76.92 77 .52 103.50 72.12 89.72 
Mean 75 .75 79.64 78.41 82.06 78.59 77.97 81.38 
S.E. 2.81 3.19 3.14 4.40 3.01 2.47 2.54 
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TABLE 1 c. The p-values for the various aspects of the viability studies 
which were conducted on immune normal splenocytes. 
p-VALUES for IMMUNE NORMAL VIABILITY 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.004 0.000 0.535 0.009 0.002 0.342 
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TABLE 2a. Effect of amphotericin 8 on 3 H-Thymidine uptake by immune 
normal 8-lymphocytes using 20 tJg /ml LPS as mitogen and 
expressed as counts per minute . 
IMMUNE NORMAL LPS (20 uglml) 
FUNGIZONE 
CONCENTRATION (uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 585 1712 3085 4084 4329 3553 3692 3692 298 
689 1867 3657 3350 3790 3316 4054 4054 410 
857 1831 3103 4037 3955 2882 4469 4469 344 
1009 3179 2959 3937 3404 3948 5769 5769 195 
965 1968 2972 3037 3649 3489 4171 4171 152 
707 1805 2408 3282 3293 3135 5297 5297 115 
12 1286 3055 4355 3541 3950 4865 4384 3505 332 
966 3619 4671 4966 2893 3349 3237 3571 455 
1396 3766 . 4343 4837 2965 3630 2926 3381 205 
1630 2617 4242 3916 3671 3641 3175 4419 420 
1269 2700 2665 3303 2774 2834 5003 4825 389 
1840 2868 4378 4230 3615 3411 4187 4415 498 
14 1004 3355 4124 4265 3763 4778 4841 3177 346 
988 3509 4017 3596 2948 3283 4033 4282 147 
1325 3738 4161 3325 4865 3638 4212 5292 300 
1828 3436 4115 4349 4876 4065 4292 3995 132 
1965 4084 5122 4379 4367 4446 3654 4278 119 
2199 3580 4498 5005 5070 4629 3713 4743 73 
Mean 1250 2927 3826 3969 3954 3716 4173 4296 274 
S.E. 112 186 182 143 258 145 174 166 31 
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TABLE 2b. Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
immune normal B-lymphocytes using 20 Jlg /ml LPS as mitogen 
and expressed as counts per minute . 
IMMUNE NORMAL LPS (20 uglml) 
AMBISOME 
CONCENTRATION (uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 4130 3222 3793 3726 3530 4958 4996 3692 298 
4638 3487 3644 3181 3511 4724 4624 4054 410 
4603 4089 4372 2930 4349 4601 4597 4469 344 
3665 3478 3826 3434 3977 3608 4751 5769 195 
4180 3620 3019 4500 5203 4467 4491 4171 152 
4411 3938 2978 4872 5117 4102 4371 5297 115 
12 4291 3877 3954 5541 4252 3580 4837 3505 332 
4270 4709 4435 3870 4266 4189 4506 3571 455 
3811 2618 3602 4591 3353 4450 4547 3381 205 
4805 3914 4581 3668 4494 3855 4451 4419 420 
6143 3907 4677 4324 3944 4679 5026 4825 389 
6357 4318 4534 3977 5267 5405 5554 4415 498 
14 7313 5434 5126 5044 4481 4576 3478 3177 346 
6970 6911 4109 4997 4646 4624 4497 4282 147 
5804 4589 4348 4997 4245 4347 6701 5292 300 
5022 4541 4851 4309 3046 4412 5353 3995 132 
5223 5403 4961 5416 4453 5223 5629 4278 119 
4619 3695 4468 4368 4889 5016 4548 4743 73 
Mean 5014 4208 4188 4319 4279 4490 4882 4296 274 
S.E. 253 231 147 178 150 118 162 166 31 
TABLE 2c . The p-values for the various aspects of the B-cell 
studies which were measured on immune normal 
splenocytes stimulated using 20 Jlg/ml LPS as the 
mitogen . 
p-VALUES for IMMUNE NORMAL LPS (20 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0 .000 0.000 0.975 0 .004 0.059 
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TABLE 3a . Effect of amphotericin Bon 3H-Thymidine uptake by immune 
normal B-lymphocytes using 10 pg/ml LPS as mitogen and 
expressed as counts per minute . 
IMMUNE NORMAL LPS (10 ug/ml) 
FUNGIZONE 
CONCENlRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 233 1355 2274 2627 3898 4961 4381 4635 123 
347 1957 3442 4236 4198 3899 4561 5908 164 
324 2199 3240 4875 5013 5410 5908 4592 246 
388 2228 3574 4252 5482 4972 4592 5626 143 
253 1291 2786 4331 4824 4624 5626 6099 210 
316 1076 3393 3766 4685 4787 6099 4381 117 
12 1011 2144 3401 4206 5204 3860 5200 5729 374 
978 1672 3524 4223 3928 4114 5373 5116 258 
448 2641 4367 4851 3852 3275 4469 4771 428 
527 2321 2846 4657 3741 2831 3674 6048 339 
777 2046 2918 2933 2364 2552 3971 5475 328 
556 1956 3023 4175 4667 3988 3859 5088 464 
14 42.3 2708 4038 4300 3729 4289 4101 3534 293 
179 3427 4372 5231 4726 3829 4185 2799 259 
143 2744 3855 3664 3561 3892 3577 2745 244 
338 2487 3006 3866 3116 3904 3978 2718 349 
556 2226 3123 3682 2415 2740 3616 4522 265 
307 2497 3620 2507 2052 3230 3043 5432 294 
Mean 429 2165 3378 4077 3914 3953 4455 4734 272 
S.E. 63 136 130 189 245 191 204 265 23 
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TABLE 3b . Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
immune normal B-lymphocytes using 1 0 ,ug/ml LPS as mitogen 
and expressed as counts per minute. 
IMMUNE NORMAL LPS (10 ug/ml) 
AMBISOME 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 2940 3978 4793 5013 5971 6227 7033 4635 123 
3961 4006 4039 4357 5708 5345 6151 5908 164 
4493 3964 4699 3817 4906 5555 5355 4592 246 
3997 3465 5278 5014 4831 5037 5242 5626 143 
4141 3859 4861 4982 4624 5245 4109 6099 210 
4232 5359 5475 4639 4742 5941 5969 4381 117 
12 2869 3755 3530 4055 3949 4618 4996 5729 374 
3937 2363 4415 3745 4034 4365 5123 5116 258 
3917 4045 2813 3357 3706 4328 4523 4771 428 
3144 3415 3250 3157 3650 3938 4290 6048 339 
2986 3402 3644 3746 3375 4278 3765 5475 328 
5019 5354 3764 3943 4059 6015 5110 5088 464 
14 5482 6289 5055 4053 3199 2661 2923 3534 293 
6056 6618 6624 3713 3863 3126 3232 2799 259 
5062 7661 6185 4393 3538 3389 5328 2745 244 
5266 6092 6455 5978 4564 4983 4894 2718 349 
4585 5455 6162 6957 5031 4540 4713 4522 265 
4089 4708 4949 6374 6256 5019 5567 5432 294 
Mean 4232 4655 4777 4516 4445 4701 4962 4734 272 
S.E. 214 324 266 246 211 234 234 265 23 
TABLE 3c. The p-values for the various aspects of the B-cell 
studies which were measured on immune normal 
splenocytes stimulated using 10 tJg/ml LPS as the 
mitogen . 
p-VALUES for IMMUNE NORMAL LPS (10 ug/rnl) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0.000 0.000 0.000 0.000 0.047 
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TABLE 4a. Effect of amphotericin B on 
3 H-Thymidine uptake by 
cyclosporine compromised B-lymphocytes using 20 ,ug/ml LPS 
as mitogen and expressed as counts per minute . 
CYCLOSPORINE LPS (20 ug!ml) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 549 2096 3109 5063 4316 4359 5700 3692 270 
926 2616 2951 4443 3935 3714 3897 4054 285 
792 1959 2865 3335 3250 2430 3481 4469 225 
741 1971 2766 3710 3590 3588 3581 5769 265 
728 1614 2746 3367 3508 2884 3842 4171 253 
468 2129 3495 3947 3889 3184 4509 5297 344 
12 502 2258 3820 3516 3911 4662 4566 5558 1031 
1669 3188 2871 3918 3262 4088 4366 3749 514 
659 2145 2938 3195 3380 3346 3983 6089 551 
829 2489 2966 3310 4248 3182 3791 5400 646 
847 2504 3401 2711 2860 2716 4327 7636 610 
1247 2546 4590 3320 2583 2381 3856 7580 662 
14 364 3078 4225 6014 4993 6452 7328 6736 431 
637 3299 4180 6639 4463 5489 8103 6237 542 
557 4289 4964 4886 5426 6805 7428 6069 142 
840 4978 5971 7024 6093 6705 8708 7069 73 
1778 6070 7240 7718 6660 7028 8749 5166 132 
906 4911 6321 5781 5857 5746 7335 5454 119 
Mean 836 3008 3968 4550 4235 4376 5419 5566 394 
S.E. 90 295 321 354 271 378 456 289 59 
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TABLE 4b. Effect of liposomal amphotericin Bon 3H-Thymidine uptake by 
cyclosporine compromised B-lymphocytes using 20 11g/ml LPS 
as mitogen and expressed as counts per minute. 
CYCLOSPORINE LPS (20 uglml) 
AMBISOME 
CONCENTRATION (uglrnl) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 4514 4119 5103 4921 4929 4335 3418 3692 270 
5367 3813 3268 3073 3867 4672 4334 4054 285 
4979 3620 3074 4050 4594 3124 3252 4469 225 
3417 3058 2820 4664 4287 4681 3165 5769 265 
3729 2726 2884 3598 4385 3402 3793 4171 253 
3991 3701 3001 3835 3921 4818 3598 5297 344 
12 4730 2958 3104 2977 2803 3246 5443 5558 1031 
3124 3639 3870 3547 3114 3760 5566 3749 514 
4427 3391 3320 4154 3392 3251 4177 6089 551 
4500 3990 3409 3889 4101 4611 4740 5400 646 
3921 3044 3128 3994 3428 4013 3962 7636 610 
3606 3517 3430 3581 4405 4514 3906 7580 662 
14 8323 4969 6492 5504 5230 6944 7045 6736 431 
6564 7194 7317 6449 4987 4585 6770 6237 542 
8769 6264 7225 7078 6454 6361 6855 6069 142 
6698 7663 6839 5096 5886 7358 6935 7069 73 
5760 6502 5767 5537 7344 6072 5181 5166 132 
7372 6568 6719 6403 4772 4312 5397 5454 119 
Mean 5211 4485 4487 4575 4550 4781 4863 5566 394 
S.E. 399 378 408 285 274 314 317 289 59 
TABLE 4c. The p-values for the various aspects of the B-cell 
studies which were measured on cyclosporine 
compromised sp lenocytes using 20 JJg /ml LPS as 
the mitogen . 
p-VALUES for CYCLOSPORINE LPS (20 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0.000 0.000 0.253 0.000 0.000 
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TABLE 5a. Effect of amphotericin B on 3H-Thymidine uptake by 
cyclosporine compromised 8-lymphocytes using 1 0 ,ug/ml LPS 
as mitogen and ex pressed as counts per minute . 
CYCLOSPORINE LPS (10 ug/ml) 
FUNGIZONE 
CONCENTRATION (ug/rnl) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 131 892 1207 1685 3399 3466 3822 4381 167 
219 1003 921 1881 2429 2485 2676 4635 345 
256 860 1718 1912 2634 2078 3045 5908 208 
283 786 1679 2287 1996 2378 2999 4592 261 
446 1197 1859 2853 2272 3103 3011 5626 229 
256 917 2144 3803 3048 2722 3421 6099 289 
12 357 2617 2924 4295 3068 3523 4220 3828 453 
1486 2466 2566 3176 3278 2874 3198 4644 537 
2369 2691 3629 2965 2961 2688 3426 3680 488 
327 2918 2938 3033 2483 2223 3451 3937 369 
1198 1620 3046 3160 2353 1940 3455 3468 374 
1249 2322 2756 2678 2975 3063 3099 4963 415 
14 12.9 3517 6234 8638 6283 4500 6239 4710 163 
846 3964 5665 7899 6826 6197 6429 4142 410 
444 5190 7879 6577 5938 5007 5944 4164 336 
846 3499 7111 5413 4547 3763 5099 5132 237 
748 6354 7564 7238 4590 6150 5152 3591 175 
768 5852 7300 8954 8019 5564 4609 4317 207 
Mean 680 2648 3841 4358 3839 3540 4072 4545 320 
S.E. 140 408 567 577 422 325 286 182 26 
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TABLE 5b. Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
cyclosporine compromised B-lymphocytes using 10 JJg /ml LPS 
as mitogen and expressed as counts per minute . 
CYCLOSPORINE LPS (10 ug/ml) 
AMBISOME 
CONCENI'RATION (ug!ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 4813 3865 3833 4244 4038 4017 4289 4381 167 
4197 3674 4610 4329 4623 4452 3408 4635 345 
4435 4373 5256 4487 4200 4354 3395 5908 208 
4179 4267 5183 4928 4184 3598 3537 4592 261 
5268 4424 4798 4699 4457 5169 3815 5626 229 
5707 4357 5042 4648 3978 4870 4470 6099 289 
12 3538 2893 2864 3027 2680 3490 3707 3828 453 
3833 2743 2707 2697 3315 4433 3802 4644 537 
4354 3598 2557 3509 2913 3467 4218 3680 488 
4397 3645 3751 3701 3672 4265 4397 3937 369 
4856 3613 3544 5008 4446 5249 4731 3468 374 
7532 4550 3691 4605 4813 5939 5820 4963 415 
14 6801 7932 7324 6762 7114 5724 5897 4710 163 
5881 7000 6973 5769 5589 5135 5394 4142 410 
6100 5629 6588 5642 5401 4506 3990 4164 336 
4033 6103 5542 6126 5503 4676 3654 5132 237 
4925 5762 5191 7068 6448 3849 2842 3591 175 
6218 4374 6773 5514 6919 5554 5602 4317 207 
Mean 5059 4595 4790 4820 4683 4542 4276 4545 320 
S.E. 259 327 349 281 300 199 211 182 26 
TABLE 5c . The p-values for the various aspects of the 8-cell 
studies which were measured on cyclosporine 
compromised splenocytes using 10 tJg /ml LPS as 
the mitogen . 
p-VALUES for CYCLOSPORINE LPS (10 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p = 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
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TABLE 6a . Effect of amphotericin B on 3H-Thymidine uptake by 
cyclophosphamide compromised B-lymphocytes using 20 
,ug/ml LPS as mitogen and expressed as counts per minute. 
CYCLOPHOSPHAMIDE LPS (20 uglml) 
FUNGIWNE 
CONCENTRATION ( uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 289 1064 1018 1142 1358 1611 1686 3692 183 
503 901 1071 1380 1092 1297 1336 4054 259 
460 954 1187 1236 1352 1182 1304 4469 330 
809 1239 2262 1127 1077 966 1517 5769 297 
605 1106 1326 1312 1320 1325 1482 4171 239 
970 1260 1395 1270 1427 1476 1520 5297 319 
12 847 2655 2516 2775 2907 2833 3390 4041 402 
910 1854 2800 2593 1913 2595 2928 4788 520 
1163 2595 3056 2344 2377 2785 3131 5289 462 
1535 2884 2910 2661 2279 2053 2364 4895 309 
972 2158 1770 2038 2485 2438 2347 3299 277 
743 1568 2915 2795 3109 2540 2063 2866 434 
14 50.9 776 2220 2135 1952 2107 3170 4891 263 
289 1586 2233 3054 2166 2490 3254 4523 142 
601 1345 2831 2916 2538 2406 3524 4639 300 
256 1973 2403 3317 2492 2879 3109 4871 132 
256 2164 2938 2900 2436 2660 3201 5149 72.6 
364 2507 2493 2966 2355 2756 2754 3830 119 
Mean 646 1699 2186 2220 2035 2133 2449 4474 281 
S.E. 90 158 167 182 148 153 189 177 29 
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TABLE 6b . Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
cyclophosphamide compromised B-lymphocytes using 20 
.ug /ml LPS as mitogen and expressed as counts per minute . 
CYCLOPHOSPHAMIDE LPS (20 ug/ml) 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1391 1346 1244 1228 1681 1532 1785 3692 183 
1339 1102 1252 1441 1219 1565 1551 4054 259 
1088 1154 1267 1157 1716 1803 1645 4469 330 
1222 905 1134 1365 1537 1425 1768 5769 297 
1301 1169 1185 1542 1740 1497 1847 4171 239 
1255 1545 1763 1729 2076 2150 1731 5297 319 
12 2670 2328 1968 2637 3068 2494 2690 4041 402 
2069 1641 2201 1818 1934 1805 2372 4788 520 
2024 1831 2572 1437 2489 2004 2273 5289 462 
1824 1922 2007 2112 1612 1860 1563 4895 309 
2529 2295 1861 1768 2110 1962 1296 3299 277 
2698 2331 1866 1818 1745 2084 2288 2866 434 
14 3262 3003 3255 2397 2919 2786 2183 4891 263 
2667 3256 3223 2628 1889 2841 1757 4523 142 
2653 2845 3372 2403 2208 2285 1950 4639 300 
2077 1850 2281 2038 2258 2322 1813 4871 132 
1852 2291 2049 2342 2369 1821 2055 5149 72.6 
2725 2484 2091 1769 1857 1484 1884 3830 119 
Mean 2036 1961 2033 1868 2024 1984 1914 4474 281 
S.E. 157 163 167 110 112 102 81 177 29 
TABLE 6c . The p-values for the various aspects of the B-cell 
studies which were measured on 
cyclophosphamide compromised splenocytes 
using 20 pg/ml LPS as the mitogen . 
p-VALUES for CYCLOPHOSPHAMIDE LPS (20 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.152 0.000 0.000 0.000 0.000 0.031 0.000 
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TABLE 7a . Effect of amphotericin B on 3H-Thymidine uptake by 
cyclophosphamide compromised B-lymphocytes using 10 
)Jg /ml LPS as mitogen and expressed as counts per minute . 
CYCLOPHOSPHAMIDE LPS (10 ug/ml) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 570 1351 1483 1837 1841 1868 1678 4381 372 
822 1414 1882 1815 1576 1577 1231 4635 300 
1029 1358 1694 1515 1366 1520 1563 5908 388 
554 1410 1882 1806 1660 1248 1408 4592 150 
651 1118 2126 1323 1135 1333 1129 5626 358 
628 1770 1495 1581 1612 1414 1056 6099 190 
12 1765 3000 2638 2737 2577 2002 2348 3280 384 
703 1972 1968 2556 1735 2136 2360 3113 232 
522 2038 . 2181 2794 1865 1834 1672 3526 348 
527 2468 2164 2057 2011 1568 4067 302 
1048 1932 2633 1775 1981 1540 1522 3516 444 
899 1918 2109 1813 1172 1051 1548 3833 339 
14 169 662 1208 1636 1933 1772 2891 3750 163 
124 920 1668 2293 1993 2362 2585 4781 97.4 
275 1129 1480 2261 2299 2300 2597 5341 336 
214 962 2125 1743 2522 1730 2582 5458 237 
170 956 1401 2235 2101 1839 2197 3840 136 
188 836 1718 2345 2404 2930 2771 3828 175 
Mean 603 1512 1881 2009 1879 1804 1900 4421 275 
S.E. 98 146 95 100 99 107 134 220 24 
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TABLE 7b . Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
cyclophosphamide compromised B-lymphocytes using 10 
,ug/ml LPS as mitogen and expressed as counts per minute. 
CYCLOPHOSPHAMIDE LPS (10 ug/ml) 
AMBISOME 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1730 1810 1459 1386 1277 1190 1479 4381 372 
1768 1589 1649 1445 1248 1190 1156 4635 300 
2213 1548 1377 1508 1242 1229 1192 5908 388 
1815 1390 1300 1288 1193 1174 1341 4592 150 
2025 1385 1357 1381 1386 1463 1290 5626 358 
1874 1784 1801 1257 1651 1580 1426 6099 190 
12 1768 2628 1580 2438 2050 2380 1996 3280 384 
2382 2122 1903 1941 2197 1641 2128 3113 232 
2592 2454 2031 1446 2093 2379 2786 3526 348 
2930 2486 2623 2342 2469 3317 2674 4067 302 
3014 2703 3386 2645 2498 2755 1670 3516 444 
3136 3335 3295 2348 2819 2460 2783 3833 339 
14 3009 2237 1824 1833 2726 3615 3249 3750 163 
2669 2673 3326 2719 3623 2788 3297 4781 97.4 
2714 3340 3496 2198 2849 2601 3149 5341 336 
2973 2745 3024 1915 2099 2551 2699 5458 237 
2707 3348 1889 1485 1653 1404 1663 3840 136 
2235 2543 1969 1803 1827 2151 1483 3828 175 
Mean 2420 2346 2183 1854 2050 2104 2081 4421 275 
S.E. 118 154 184 115 162 181 181 220 24 
TABLE 7c. The p-values for the various aspects of the B-cell 
studies which were measured on 
cyclophosphamide compromised splenocytes 
using 10 JJg /ml LPS as the mitogen. 
p-VALUES for CYCLOPHOSPHAMIDE LPS (10 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
138 
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TABLE 8a. Effect of amphotericin B on 3H-Thymidine uptake by immune 
normal B-lymphocytes using 2 .5 JJg /ml Con A as mitogen and 
expressed as counts per minute. 
IMMUNE NORMAL CON A (2.5 uglml) 
FUNGIZONE 
CONCENTRATION (uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1940 3307 3713 4881 6140 3562 4090 4090 140 
717 2397 7700 4902 4110 3185 3745 3745 125 
636 2081 4251 4689 4204 3510 3561 3561 113 
1107 1920 3355 4433 4023 4155 5748 5748 160 
1107 3063 4871 4777 3502 4364 4604 4604 186 
1066 3030 3489 3668 3843 4615 4704 4704 115 
12 395 3183 5556 4722 4667 6694 4781 4565 247 
331 3169 4598 6442 5969 6803 5212 5955 267 
185 2355 5161 4888 5796 6066 3596 4780 276 
396 2292 5904 6055 5596 6381 5778 3579 198 
2363 1355 6284 5607 5549 5153 4500 4849 297 
381 3122 6829 4962 4923 5174 4949 4658 339 
13 1196 2440 5960 5403 6018 6106 6226 4143 802 
541 4718 5143 5518 5899 4171 5044 4310 715 
719 5516 5370 5335 4388 4095 3011 4919 619 
711 4552 4832 3409 3713 2907 3731 5226 650 
2321 3963 4605 3353 2850 3648 3932 5825 742 
1310 4849 4395 4412 4517 4602 4793 4311 616 
13a 816 3215 5127 5416 5297 6213 6404 8645 765 
638 5958 5396 4703 4571 6369 5607 7084 708 
2688 5771 6514 4055 4121 4635 6303 5607 668 
1022 4620 5755 3929 4041 6080 6760 5158 398 
2245 5499 4678 4972 3920 3659 6447 4970 289 
525 5026 4656 5273 3868 4184 5867 5285 418 
Mean 1056 3642 5248 4867 4647 4847 4975 5013 411 
S.E. 149 276 218 164 189 247 219 230 50 
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TABLE 8b . Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
immune normal B-lymphocytes using 2 .5 JJg /ml Con A as 
mitogen and expressed as counts per minute. 
IMMUNE NORMAL CON A (2.5 uglml) 
AMBISOME 
CONCENTRATION (uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 6030 3707 3455 3802 3404 3888 4698 4090 140 
4987 3422 5307 4756 3863 4051 4486 3745 125 
3800 4956 3677 3506 4115 2808 3533 3561 113 
3658 4013 3940 4425 3748 4173 4247 5748 160 
4996 3749 3663 4985 3966 5160 4564 4604 186 
5343 3801 3086 3612 3819 4456 4719 4704 115 
12 5498 7661 5885 5891 5532 6219 4958 4565 247 
7856 6771 6924 6872 6442 4801 4608 5955 267 
5568 5952 6394 5928 6298 4364 4529 4780 276 
6309 4827 4741 6917 6387 6945 4106 3579 198 
7912 4832 5618 5257 6527 6029 4930 4849 297 
4311 3955 5834 6907 5284 4943 4389 4658 339 
13 4540 5346 5517 6045 5147 4787 5396 4143 802 
4973 4995 5704 6125 4507 4619 4831 4310 715 
4661 6559 5868 5861 5541 5453 5523 4919 619 
6690 4722 5589 5646 5431 5729 5193 5226 650 
7254 5674 4532 5290 4750 6115 5884 5825 742 
10199 9153 6184 6199 5732 4832 5519 4311 616 
13a 5155 5461 4674 4556 5328 6383 6464 8645 765 
4519 4350 4819 4216 5734 6154 6488 7084 708 
4935 3704 3499 4407 5409 6202 6086 5607 668 
4788 4359 3576 4401 3621 5309 5483 5158 398 
4235 4215 4259 4004 3774 3492 5342 4970 289 
4998 4507 4487 4538 6297 5154 5073 5285 418 
Mean 5551 5029 4884 5173 5027 5086 5044 5013 411 
S.E. 309 283 220 215 210 208 149 230 50 
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TABLE Be . The p-values for the various aspects of the T-cell studies 
which were measured on immune normal splenocytes 
stimulated using 2 .5 JJg /ml Con A as the mitogen. 
p-VALUES for IMMUNE NORMAL CON A (2.5 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0.000 0.000 0.000 0.000 0.013 
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TABLE 9a . Effect of amphotericin B on 3 H-Thymidine uptake by immune 
normal B-lymphocytes using 1.25 tJg /ml Con A as mitogen and 
expressed as counts per minute. 
IMMUNE NORMAL CX)N A (1.25 ug!ml) 
FUNGIWNE 
CONCENTRATION (ug!ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1477 3411 3362 4023 4699 4557 5416 5416 158 
1738 3020 3368 4459 4014 5388 4710 4710 162 
1726 3028 4154 3815 3545 4291 5430 5430 153 
1465 2841 3905 4791 4877 4264 5152 5152 102 
1665 3287 5180 4718 4336 3807 5637 5637 110 
1672 3434 4140 4044 4090 3442 4956 4956 80.2 
12 577 2693 5213 5495 6334 6893 5721 4332 385 
495 3356 4395 6424 7425 7113 5805 4955 495 
478 3070 4192 5007 6155 5268 5696 5210 302 
207 2431 4026 4148 5884 4359 4278 3661 220 
237 3744 4620 4062 4161 3581 4340 3076 294 
370 2609 4731 5275 4471 3954 3419 3343 466 
13 1980 2782 4350 4442 3692 5922 6743 6674 1050 
806 2444 2929 4285 3867 3944 6842 7666 771 
3521 4250 5316 3787 4446 3465 5708 5472 763 
1257 3991 4941 3671 4355 3186 4209 7780 486 
241 3976 4567 4498 4884 4140 5313 6347 438 
243 3108 4635 6360 5352 4555 5539 5748 684 
13a 2552 5288 5173 4926 5049 5770 6327 7262 692 
2525 5633 5227 4778 4552 5456 7437 5622 823 
2750 4220 6241 5087 5645 4990 6374 6892 774 
408 3707 5601 5264 4275 4415 5044 4526 476 
1274 4194 4554 4807 3322 3781 4544 4295 649 
1001 4355 5449 4514 3776 4706 4123 5624 628 
Mean 1278 3534 4595 4695 4717 4510 5282 5408 465 
S .E. 189 170 158 147 202 190 186 256 56 
143 
TABLE 9b . Effect of liposomal amphotericin Bon 3 H-Thymidine uptake by 
immune normal B-lymphocytes using 1.25 tJg /ml Con A as 
mitogen and expressed as counts per minute. 
IMMUNE NORMAL CON A (1.25 uglml) 
AMBISOME 
CONCENlRA TION ( uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 6030 3863 4519 4528 4500 3650 4312 5416 158 
4254 5002 3203 4353 5137 3833 3626 4710 162 
4184 4355 4020 3476 4143 3445 4523 5430 153 
4223 3332 3950 3479 4821 5548 4736 5152 102 
3765 2860 2590 3805 4519 5351 4307 5637 110 
4120 3131 2992 3281 3884 4311 4120 4956 80.2 
12 5909 6070 5104 5921 4006 4254 4775 4332 385 
5480 6148 7346 4515 4438 4454 3948 4955 495 
6830 6755 6614 5042 4728 3898 5281 5210 302 
6455 5089 4614 6184 3950 4300 4387 3661 220 
6098 5305 5112 5898 4068 4412 3170 3076 294 
6711 5368 6218 5734 5200 4156 5875 3343 466 
13 5143 4213 4384 6202 5355 5927 8082 6674 1050 
4850 4195 5379 5679 5732 5368 5640 7666 771 
3694 3860 5007 4743 4597 5161 7196 5472 763 
3971 2735 3935 4186 4149 4427 6080 7780 486 
4747 3411 3931 4494 4382 5201 5685 6347 438 
5216 3504 3087 5283 4331 5014 5294 5748 684 
13a 5728 5597 4857 4516 4182 4448 7558 7262 692 
4879 5281 4240 4686 4642 4001 5585 5622 823 
4486 4133 3616 6301 4563 3833 4147 6892 774 
5485 5337 3939 4362 3463 3218 4100 4526 476 
7186 5073 5433 4223 3400 3528 5712 4295 649 
10067 4010 5366 5443 3996 2596 4909 5624 628 
Mean 5396 4526 4686 4847 4448 4360 5127 5408 465 
S.E. 290 224 236 186 115 160 251 256 56 
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TABLE 9c. The p-values for the various aspects of the T-cell studies 
whic h were measured on immune normal splenocytes 
stimulated using 1.25 pg/ml Con A as the mitogen. 
p-VALUES for IMMUNE NORMAL CON A (1.25 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
p-value Drug Dose Exp X X 
Dose Ex 
p= 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
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TABLE lOa. Effect of amphotericin B on 3H-Thymidine uptake by 
cyclosporine compromised B-lymphocytes using 2.5 
pg/ml Con A as mitogen and expressed as counts per 
minute. 
CYCLOSPORINE CON A (2.5 ug/ml) 
FUNGIZONE 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 596 2107 2565 3964 3677 4736 4042 4090 256 
598 1274 3563 4241 4030 4575 3879 3745 287 
580 1592 3368 4572 3235 3266 4363 3561 305 
466 1400 2224 3614 4448 3767 4625 5748 329 
619 1417 3450 4217 4113 3319 4043 4604 343 
403 2389 3274 4367 2730 3307 3589 4704 299 
12 147 977 3148 5202 5542 4631 6235 7986 548 
193 1488 3825 5480 4822 6406 5990 6320 521 
155 2265 4652 6369 4034 3981 4677 4801 353 
80.3 1931 5584 4510 4305 4988 7294 4234 343 
145 1351 3641 5247 7110 5217 6943 4535 326 
153 1670 4251 4326 4406 5028 3643 4466 289 
13 333 3075 4927 5273 8005 7754 6250 6140 348 
203 3186 5361 5753 5785 6245 6502 6385 347 
225 4793 5471 4878 5321 5690 6451 6739 342 
452 3890 3390 3869 4206 4820 6268 5400 278 
197 3058 5190 5223 4337 6136 5894 6308 312 
348 2667 4895 5691 5964 5395 7150 5018 333 
13a 2053 4597 4966 5379 4374 4873 4880 5504 657 
1092 4515 5252 6279 5518 5495 5491 6997 383 
801 4726 5735 5849 6125 5074 5120 5677 380 
768 4323 5107 6353 6432 5649 5584 5145 329 
454 1141 4207 3936 4739 5824 4942 6048 366 
350 819 4222 4945 4461 3772 6452 7511 428 
Mean 476 2527 4261 4985 4905 4998 5429 5486 363 
S.E. 86 270 205 167 250 224 235 239 19 
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TABLE 10b . Effect of liposomal amphotericin B on 3H-Thymidine 
uptake by cyclosporine compromised B-lymphocytes 
using 2. 5 JJg /ml Con A as mitogen and expressed as 
counts per minute . 
CYCLOSPORINE CON A (2.5 ug!ml) 
AMBISOME 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 4435 3618 4928 4244 4742 4156 3798 4090 256 
4712 3737 4066 4144 7148 4361 3873 3745 287 
2786 3373 4511 3834 4969 4160 4793 3561 305 
3408 3608 3796 3654 4041 3986 4402 5748 329 
4498 2461 3880 3885 4032 4638 3619 4604 343 
2962 3314 2984 3952 3793 5110 4807 4704 299 
12 4053 5381 5087 4040 5395 4731 5325 7986 548 
6914 4007 3352 4636 4473 5762 4647 6320 521 
3911 5491 3108 6045 5808 5891 4782 4801 353 
5692 3312 3237 5827 4779 3671 4994 4234 343 
4421 4241 3696 4226 3897 3541 4788 4535 326 
3748 4820 3827 2880 3955 4442 4106 4466 289 
13 3658 3480 4610 5061 5979 5916 7198 6140 348 
4201 3981 4630 5163 6107 7362 5561 6385 347 
3881 4429 5305 5620 6532 5301 6180 6739 342 
4242 4584 5486 4955 5047 5413 5590 5400 278 
5352 4628 5203 4423 5843 4940 4747 6308 312 
6631 5278 5109 5548 4570 5502 4705 5018 333 
13a 5616 5388 3863 4021 3730 4266 5318 5504 657 
6306 4408 5224 4179 3770 4078 5956 6997 383 
5323 5246 4428 4392 5252 3739 5064 5677 380 
6337 5562 5326 5344 5892 6175 5916 5145 329 
7795 5705 5067 4790 5176 6237 5946 6048 366 
11827 6357 5537 5177 5479 5183 5719 7511 428 
Mean 5113 4434 4428 4585 5017 4941 5076 5486 363 
S.E. 394 199 166 158 196 197 172 239 19 




The p-values for the various aspects of the T-cell 
studies which were measured on cyclosporine 
compromised splenocytes using 2.5 Jlg /ml Con A as the 
mitogen. 
p-VALUES for CYCLOSPORINE CON A (2.5 ug/ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
Drug Dose Exp X 
Dose 
0.000 0.000 0.000 0.000 0.248 0.001 0.002 
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TABLE 11a . Effect of amphotericin B on 3 H-Thymidine uptake by 
cyclosporine compromised B-lymphocytes using 1. 25 
,ug/ml Con A as mitogen and expressed as counts per 
minute . 
CYCLOSPORINE CON A (1.25 ug/ml) 
FUNGIWNE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1437 2841 2713 3700 3380 4060 4374 5416 411 
1253 2169 2162 3054 3336 3840 3634 4710 292 
1294 1299 2952 3134 3346 3902 2875 5430 383 
952 1828 2985 3888 3216 3005 3346 5152 260 
948 1562 3608 3570 3627 3403 3531 5637 298 
1188 2405 3544 3303 3421 3147 4061 4956 234 
12 216 1510 3762 5338 5873 7159 7122 5572 546 
420 2666 2999 4058 5964 4639 6875 6233 465 
1383 3270 3320 5511 4934 6055 5529 7426 440 
1584 2952 5294 4133 4698 5526 6069 6207 508 
867 3037 4765 5770 4210 4557 4821 6962 526 
1374 4484 6250 6135 4715 3847 4872 7310 142 
13 227 3110 5079 7459 6355 7344 7550 7071 366 
387 3513 5317 6498 5460 6619 6945 5622 360 
291 3252 5072 5270 5961 5580 5935 7976 428 
222 1773 4585 3921 4870 4635 6147 9062 314 
437 728 3255 3308 5056 5683 7321 6158 272 
110 4309 3682 4621 5292 4709 5711 6511 440 
13a 979 3569 5374 4998 4667 6038 6444 9362 615 
596 3664 4605 4621 5548 4884 5875 8757 497 
556 3758 4346 5376 4380 6038 6171 7842 338 
615 3298 4854 5531 4296 4146 6126 8445 299 
178 2698 6161 6078 4296 3670 6583 7844 376 
356 3452 6350 6218 6426 5192 6595 6807 363 
Mean 745 2798 4289 4812 4722 4903 5605 6770 382 
S.E. 97 197 242 248 205 251 276 276 23 
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TABLE 11b. Effect of liposomal amphotericin B on 3H-Thymidine 
uptake by cyclosporine compromised 8-lymphocytes 
using 1.25 Jig/ml Con A as mitogen and expressed as 
counts per minute. 
CYCLOSPORINE CON A (1.25 ug/ml) 
AMBISOME 
CONCENTRATION (ug/ml} 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 3720 4235 4582 3765 3010 3608 3722 5416 411 
4554 4361 4248 3424 3418 4363 3546 4710 292 
4704 5279 4122 2985 3416 4071 5089 5430 383 
4982 4482 3253 3697 4571 4156 3897 5152 260 
4548 3383 3463 3856 4840 3816 3118 5637 298 
7034 3870 4192 4212 5192 5040 3901 4956 234 
12 5782 4897 5637 6564 5214 4641 5258 5572 546 
5656 5874 5943 5991 4709 6270 6249 6233 465 
6677 5437 5795 5668 4757 6029 7112 7426 440 
5002 5215 4696 5632 5093 5632 8573 6207 508 
5327 4533 5024 5128 5908 6331 5288 6962 526 
7637 5883 5428 7196 5973 5220 5010 7310 142 
13 3998 3900 4332 5421 5387 4821 6940 7071 366 
3541 3300 4713 4921 5575 4622 7424 5622 360 
4817 4668 5760 4340 5183 4793 7502 7976 428 
4158 5300 5437 5254 3653 6460 5865 9062 314 
5078 4545 6704 4356 3647 5448 6198 6158 272 
5910 5428 5528 4659 5017 5979 5339 6511 440 
13a 5494 5086 7339 7125 5482 5926 7007 9362 615 
4574 5443 5214 5626 6729 5723 7150 8757 497 
4749 4245 4936 5071 4943 5639 6026 7842 338 
4070 3567 5053 5842 5746 4098 5232 8445 299 
4967 4316 5079 5442 5186 4912 6423 7844 376 
8463 4375 5149 5567 6243 4681 5295 6807 363 
Mean 5227 4651 5068 5081 4954 5095 5713 6770 382 





The p-values for the various aspects of the T-cell 
studies which were measured on cyclosporine 
compromised splenocytes using 1.25 ,ug/ml Con A as 
the mitogen . 
p-VALUES for CYCLOSPORINE CON A (1.25 ugiml) 
(Fungizone and ArnBisome) 
Drug Drug Dose 
Drug Dose Exp X X 
Dose Ex 
0.000 0.000 0.000 0.000 0.038 0.000 0.544 
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TABLE 12a . Effect of amphotericin B on 3 H-Thymidine uptake by 
cyclophosphamide compromised B-lymphocytes using 
2 .5 pg/ml Con A as mitogen and expressed as counts 
per minute. 
CYCLOPHOSPHAMIDE CON A (2.5 ug/ml) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 1238 2284 2437 2270 2549 2390 2506 4090 205 
1994 2270 2329 2956 3373 1721 2218 3745 307 
1267 2920 2687 2927 2649 2005 1463 3561 365 
2031 2627 3030 2926 2758 2270 1601 5748 367 
1067 2127 3230 3615 2555 2308 2149 4604 348 
1015 2712 3679 3347 3886 2454 1868 4704 258 
12 523 2762 2997 5086 3762 3935 3543 6442 389 
308 3229 4232 3036 2579 2984 3820 6851 463 
477 2482 3900 3890 3578 3635 5149 6224 458 
461 2024 3308 3756 3307 3281 4049 5886 528 
783 3958 4184 3647 3377 2895 3271 6450 551 
692 2068 4341 3705 3268 3150 3473 4365 455 
13 2595 4744 5332 4301 3580 4268 4849 7090 402 
5786 4397 4707 4416 4324 3939 4243 6321 432 
2086 3356 4309 5433 3333 3541 3140 6382 289 
3199 4091 3441 3906 3285 3264 3675 4733 193 
2241 3830 3542 2837 2630 2765 2792 6224 249 
1656 3177 3936 2788 2776 2281 3472 6069 316 
Mean 1434 3059 3646 3602 3143 2949 3182 5694 365 
S.E. 210 199 189 195 118 172 251 273 25 
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TABLE 12b. Effect of liposomal amphotericin B on 3H-Thymidine 
uptake by cyclophosphamide compromised B-
lymphocytes using 2.5 Jlg /ml Con A as mitogen and 
expressed as counts per minute. 
CYCLOPHOSPHAMIDE CON A (2.5 ug/ml) 
AMBISOME 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 2687 2070 2674 3608 3619 2218 1968 4090 205 
3160 2160 2769 2530 3267 2009 2374 3745 307 
2817 1431 3299 1610 5373 2401 688 3561 365 
2792 2158 4307 3849 3898 2887 2333 5748 367 
3162 2640 3781 3414 3427 3133 2546 4604 348 
3516 2721 3812 2939 3031 3522 2627 4704 258 
12 4246 3372 2984 3560 3066 2927 3893 6442 389 
4093 3816 3999 3146 3461 3085 3063 6851 463 
3011 3550 2946 3743 3401 3492 4167 6224 458 
3103 2956 3268 4092 4303 2874 3038 5886 528 
2917 3074 3492 3519 4476 4818 3650 6450 551 
3030 3711 2739 3696 3714 4162 3457 4365 455 
13 3655 2583 3106 2716 2507 2795 2718 7090 402 
2990 3171 2265 2546 2787 2843 2314 6321 432 
2125 2628 2446 2959 2442 3099 2923 6382 289 
2687 2072 2624 2614 2632 2701 3070 4733 193 
3224 2212 2405 2869 2965 2748 3165 6224 249 
4215 2378 1832 2787 2440 3723 3947 6069 316 
Mean 3191 2700 3042 3122 3378 3080 2886 5694 365 





The p-values for the various aspects of the T-cell 
studies which were measured on cyclophosphamide 
compromised splenocytes using 2. 5 .ug/ml Con A as the 
mitogen. 
p-VALUES for CYCLOPHOSPHAMIDE CON A (2.5 uglrnl) 
(Fungizone and AmBisome) 
Drug Drug Dose 
Drug Dose Exp X X 
Dose Ex 
0.480 0.000 0.000 0.000 0.000 0.000 0.006 
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TABLE 13a. Effect of amphotericin 8 on 3H-Thymidine uptake by 
cyclophosphamide compromised 8-lymphocytes using 
1.25 pg/ml Con A as mitogen and expressed as counts 
per minute . 
CYCLOPHOSPHAMIDE CON A (1.25 ug/ml) 
FUNGIZONE 
CONCENTRATION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 2533 2895 3911 3571 3270 2020 2486 5416 169 
1307 2955 3430 3630 3085 2649 3254 4710 320 
1106 3294 3774 3836 2839 2656 3034 5430 341 
3006 3744 4268 3434 3558 2420 2875 5152 317 
2089 2524 4368 3058 3311 2458 2648 5637 361 
2530 2898 3374 3036 3510 2844 2491 4956 237 
12 688 2931 3904 3748 2843 4462 3773 5139 472 
835 3204 3889 3500 2829 3834 3315 6062 437 
1221 3059 4129 3993 2596 3272 2751 4263 332 
336 2692 4373 3706 2695 3230 3397 5646 427 
1015 4222 3399 4367 3958 2632 4647 4839 491 
710 3169 3912 3960 4940 3300 3296 7068 429 
364 
13 1980 4274 5063 4500 3694 2698 2591 6231 
2165 4056 4005 3824 3466 2715 2516 5593 268 
2495 3282 3583 4270 2882 2915 2694 6656 233 
1873 2829 2860 2989 2797 3401 3008 6937 281 
2476 4119 2930 3094 3163 3240 2947 7253 313 
2355 3955 4250 3992 3319 3470 3871 7530 385 
Mean 1707 3339 3851 3695 3259 3012 3089 5807 343 
S.E. 190 134 126 108 134 136 135 224 21 
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TABLE 13b. Effect of liposomal amphotericin B on 
3H-Thymidine 
uptake by cyclophosphamide compromised B-
lymphocytes using 1.25 pg/ml Con A as mitogen and 
expressed as counts per minute. 
CYCLOPHOSPHAMIDE CON A (1.25 ug/ml) 
AMBISOME 
CONCENfRA TION ( ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.5 0.0 IN-C BG 
10 3242 3148 3220 2415 3396 2561 2538 5416 169 
3853 2787 3609 2912 2965 2684 2060 4710 320 
3583 2660 3520 2834 3507 2693 2711 5430 341 
3527 2735 2734 2766 2756 2260 2581 5152 317 
3304 2475 2714 2607 3040 2476 2220 5637 361 
5584 2428 2945 3411 3034 3967 3348 4956 237 
12 3584 4370 3278 4243 3997 4670 4051 5139 472 
3088 2735 4536 5320 3896 3386 3943 6062 437 
2595 3361 3982 4721 4037 3354 3307 4263 332 
2557 2710 4109 4563 4395 2345 3443 5646 427 
2727 2956 3209 3997 2972 3293 3382 4839 491 
3558 2790 3431 3946 3123 3234 2895 7068 429 
364 
13 4436 4543 3543 4165 4314 4358 4879 6231 
4612 3122 4015 3799 4783 4428 4809 5593 268 
3393 2550 4064 3991 3670 3445 4320 6656 233 
3168 3733 5524 3152 4048 4233 4792 6937 28 1 
4145 3931 5919 4468 4404 4386 4034 7253 313 
4170 3629 4676 4156 3624 3745 4091 7530 385 
Mean 3618 3148 3829 3743 3664 3418 3522 5807 343 
S.E. 180 152 207 194 142 187 211 224 21 




The p-values for the various aspects of the T-cell 
studies which were measured on cyclophosphamide 
compromised splenocytes using 1 .25 11g/ml Con A as 
the mitogen . 
p-VALUES for CYCLOPHOSPHAMIDE CON A (1.25 ug!ml) 
(Fungizone and AmBisome) 
Drug Drug Dose 
Drug Dose Exp X 
Dose 
0.000 0.000 0.000 0.000 0.000 0.000 0.010 
157 
TABLE 14a. Effect of amphotericin B on immune normal 
macrophages as measured by 3H-Thymidine uptake by 
thymocytes stimulated by undiluted supernatant 
contain ing the lnterleukin-1 produced by the 
macrophages and expressed as counts per minute. 
IMMUNE NORMAL ll...-1 (1:1) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12a 33.4 76.3 134 147 183 184 
50.4 55.1 122 91.1 286 70.5 
33.3 47.2 100 170 141 256 
32.7 60.0 139 243 234 205 
41.7 49.1 100 140 206 296 
31.8 52.0 141 126 242 185 
38.3 78.5 129 173 185 151 
42.2 69.8 83.9 175 172 219 
30.0 125 205 226 171 206 
12 95.3 96.4 149 142 139 160 
51.7 99.2 179 165 210 177 
61.0 65.8 157 162 305 174 
65.1 61.7 109 161 222 182 
42.2 69.3 110 136 235 152 
35.8 77.4 142 143 207 159 
13 93.4 99.1 154 208 242 160 230 
73.5 69.8 164 209 167 138 159 
94.0 104 160 163 363 216 189 
60.1 65.5 90.8 222 260 336 224 
53.2 41.9 187 217 154 250 254 
46.5 69.7 141 180 149 158 274 
60.7 100 115 166 113 227 160 
47.4 89.0 160 253 229 270 346 
Mean 52.8 74.9 138 175 209 197 230 
S.E. 4.2 4.4 6.5 8.4 12.3 12.0 22.2 
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TABLE 14a . (continued) 
BG 
12a 15.9 48.0 68.5 41.3 35.3 46.8 
15.0 33.2 31.2 83.5 32.8 53.1 
24.7 48.6 55.4 33.6 45.9 54.5 
12 47.6 42.3 71.3 61.9 58.8 64.2 
45.4 57.6 62.5 21.2 31.3 48.2 
13 216 149 89.6 150 82.7 
121 72.5 79.9 138 108 
74.2 94.8 89.7 72.7 84.3 
29.6 65 .0 41.2 76.0 56.2 
Mean 65.5 9.2 56.1 78.2 82.8 
S.E. 21.9 12.7 8.1 12.9 10.6 
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TABLE 14b. Effect of liposomal amphotericin B on immune normal 
macrophages as measured by 3H-Thymidine uptake by 
thymocytes stimulated by undiluted supernatant 
containing the lnterleukin-1 produced by the 
macrophages and expressed as counts per minute . 
IMMUNE NORMAL IL-l (1 :1) 
AMBISOME 
CONCENI'RA TION (ug/rnl) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12a 76.9 291 340 597 209 215 
181 250 296 329 225 256 
224 274 283 255 172 210 
311 239 171 254 251 173 
288 311 256 207 286 190 
315 245 247 298 164 331 
238 324 230 187 163 364 
451 247 247 374 128 247 
375 235 188 382 143 435 
12 134 163 182 251 240 312 
153 263 295 166 281 306 
246 104 210 155 258 267 
199 148 107 143 194 266 
196 132 139 95.4 167 208 
255 150 120 173 252 230 
13 200 195 198 169 146 233 229 
317 201 327 160 143 300 231 
317 270 150 161 179 230 275 
188 323 267 193 232 175 275 
164 258 195 188 204 276 187 
204 177 290 260 224 155 184 
138 300 233 256 218 205 188 
362 384 258 217 326 128 208 
Mean 241 238 227 229 208 248 222 






















70.2 54.3 87.4 35.3 46.8 
61.2 30.1 68.4 32.8 53.1 
121 47.8 113 45.9 54.5 
28 .5 39.3 31.5 48.1 44.5 
41.7 40.7 35.7 51.5 60.9 
59.4 121 87 .9 93.0 88.6 104 
71. 8 63.6 71.2 76.6 57.5 67.2 
92.6 98.1 99.1 68.0 74.2 98.3 
66.8 42.6 59.5 49.2 81.2 98 .1 
68.1 59.7 72.6 55.6 62.4 91.9 
9.0 10.1 9.2 6.6 5.2 8.3 
The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with undiluted supernatant 
produced by macrophages from immune normal 
splenocytes. 
p-VALUES for IMMUNE NORMAL IL-l (1:1) 





p = 0.000 0.000 0.000 
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TABLE 15a. Effect of amphotericin 8 on immune normal 
macrophages as measured by 3 H-Thymidine uptake by 
thymocytes stimulated by 1:2 diluted supernatant 
containing the lnterleukin-1 produced by the 
macrophages and expressed as counts per minute. 
IMMUNE NORMAL IL-l (1 :2) 
FUNGIZONE 
CONCENI'RATION (uglml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12a 69.9 107 212 119 145 252 
42.1 85.8 222 182 115 266 
37.0 96.2 215 98.4 157 181 
53.9 119 314 134 188 130 
47.3 76.2 120 196 185 136 
21.9 97.1 119 161 312 170 
37.9 142 364 219 233 305 
60.2 i16 171 207 162 267 
37.9 111 195 174 203 113 
12 54.6 75.2 64.5 96.3 134 166 
52.3 51.5 102 107 149 119 
54.2 76.7 117 162 208 251 
74.4 113 144 178 211 184 
85.6 128 187 231 189 169 
77.4 225 301 247 185 269 
13 111 130 93.9 112 149 135 145 
89.2 77.2 101 104 182 168 181 
138 107 Ill 103 115 69.4 112 
70.8 78.6 114 180 !51 217 106 
122 77.0 134 170 177 85.1 134 
59.0 80.8 88.1 140 173 195 141 
86.5 67.9 94.4 115 141 147 212 
76.4 113 160 121 250 181 247 
Mean 67.8 102 163 !55 179 182 160 
S.E. 6.0 7.4 16.5 9.5 9.4 13.2 17.5 
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TABLE 15a . (continued I 
BG 
12a 53.8 56.5 51.6 62.5 62.1 63 .0 
62.7 56.8 67 .5 44.5 81.7 47.4 
38.0 64.1 48 .9 43.1 43 .9 57 .2 
12 34.0 50.4 30.2 50.0 45.5 53.7 
36.3 38.9 36.2 28 .7 47.5 43.8 
13 46.9 63.8 81.7 37.7 65.4 71.5 83.4 
53.0 59.6 87.8 36.7 64.2 76.6 56.3 
47.2 30.3 40.5 40.1 55.4 54.4 128 
56.0 67 .8 40.9 34.3 45.2 68.0 59.6 
Mean 47.5 54.2 5 .9 42.0 56.8 59.5 81.8 
S.E. 3.3 4 .1 6.8 3.3 4 .2 3.7 16.5 
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TABLE 15b. Effect of liposomal amphotericin B on immune norma l 
macrophages as measured by 3H-Thymidine uptake by 
thymocytes stimulated by 1:2 diluted supernatant 
containing t he lnterleukin-1 produced by the 
macrophages and expressed as counts per minute . 
IMMUNE NORMAL IL-l (1 :2) 
AMBISOME 
CONCENTRATION (ug/rnl) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12a 213 246 265 306 167 598 
280 427 293 237 161 163 
230 386 129 192 187 141 
256 195 182 303 135 165 
562 218 678 332 202 162 
224 530 207 249 212 381 
216 252 156 189 131 208 
337 225 260 148 142 191 
324 244 255 194 133 254 
12 116 193 349 !50 259 351 
168 253 291 266 180 124 
201 131 122 !51 201 !54 
166 203 230 127 161 222 
167 166 131 196 175 113 
403 219 125 238 185 138 
13 202 161 179 117 135 136 205 
145 268 307 127 167 169 177 
358 247 240 167 214 207 189 
!53 251 100 232 110 !57 120 
249 208 202 90.9 127 245 244 
136 199 215 216 167 203 !53 
253 261 222 187 !52 185 175 
410 221 230 185 187 179 176 
Mean 251 248 233 200 169 211 180 
S.E. 22.3 18.5 24.5 13.3 7.3 22.3 12.8 





















69.6 63.3 69.9 35.4 77.4 
48.5 44.9 112 42.2 32.4 
71.6 39.0 72 .2 34.9 86.6 
52.9 60.4 50.5 39.2 43.1 
64.2 102 60.3 45.4 68.6 
85.9 117 85 .4 
75.6 101 78.4 
62.3 104 55.9 
91.6 50.4 49. 
69.1 75.6 67 .2 
4.7 9.8 8.7 
The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with 1 :2 diluted supernatant 
produced by macrophages from immune normal 
splenocytes . 
p-VALUES for IMMUNE NORMAL IL-l (1 :2) 
(Fungizone and AmBisome) 
p-value 
Drug 
Drug Dose x 
Dose 
p= 0.000 0.112 0.000 
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TABLE 16a. Effect of amphotericin B on cyclosporine compromised 
macrophages as measured by 3H-Thymidine uptake by 
thymocytes st imulated by undiluted supernatant 
containing the lnterleukin-1 produced by the 
macrophages and expressed as counts per minute . 
CYCLOSPORINE IL-l (1 :1) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 77.8 51.0 162 148 197 230 
64.3 85.2 163 129 241 186 
55.5 75.0 139 191 220 183 
42.6 63.0 96.2 339 238 237 
45.2 73 .8 132 183 310 202 
30.3 48.6 147 214 368 224 
13 92.0 128 !57 243 320 273 199 
55.3 152 206 276 201 335 259 
88.4 95.9 195 208 272 323 421 
76.5 109 213 220 170 286 346 
71.5 105 181 215 218 343 425 
58.2 133 170 199 156 477 317 
80.6 100 150 278 189 298 328 
57.3 114 93.4 204 222 250 240 
Mean 64.8 95.3 157 218 237 275 317 
S .E. 5.2 8.3 9.6 14.4 16.2 21.0 28.9 
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TABLE 16a. (continued) 
BG 
12 61.5 53.1 137 89.6 76.5 66.7 
47.8 59.6 61.5 59.8 185 51.3 
13 32.7 61.2 63.5 60.1 88.0 86.6 85.4 
37.1 57.9 60.2 43.5 52.8 124 107 
42.3 59.6 74.1 46.5 72.4 84.9 64.5 
63.8 67.0 58.4 96.6 69.9 71.0 Ill 
Mean 47.5 59.7 75.8 66.0 90.8 80.8 92.0 
S.E. 5.2 1.8 12.5 9.0 19.4 10.1 10.7 
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TABLE 16b. Effect of liposomal amphotericin B on cyclosporine 
compromised macrophages as measured by 3H-
Thymidine uptake by thymocytes stimulated by 
undiluted supernatant containing the lnterleukin-1 
produced by the macrophages and expressed as counts 
per minute. 
CYCLOSPORINE IL-l (1:1) 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 236 351 371 449 475 314 
250 195 214 443 220 364 
287 379 380 324 264 263 
339 205 160 288 316 221 
385 229 269 320 349 247 
293 266 284 371 392 218 
13 335 394 324 279 259 227 168 
531 430 456 224 278 140 226 
382 316 301 341 265 168 197 
294 331 438 213 244 177 188 
432 319 203 346 196 228 177 
326 345 314 386 195 226 195 
372 255 271 334 231 299 136 
340 441 375 208 289 203 193 
Mean 343 318 311 323 284 235 185 


















50.2 42.2 54.2 68.9 48.0 
80.7 115 81.7 73.1 76.7 
80.3 89.5 Ill 79.4 92.6 105 
90.7 53.7 62 .0 146 146 125 
127 80.5 73 .4 58.1 73.1 80.1 
80.7 56.9 60.6 64.8 93.0 58 .0 
84.9 73.0 73 .8 81.7 88.2 92.0 
10.1 11.1 8.5 13.2 13.4 14.6 
The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with undiluted supernatant 
produced by macrophages from cyclosporine 
compromised splenocytes . 
p-VALUES for CYCLOSPORINE IL-l (1:1) 
(Fungizone and AmBisome) 
Drug 
p-value Drug Dose x 
Dose 
p = 0.000 0.000 0.000 
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TABLE 17a. Effect of amphoteric in B on cyclosporine compromised 
macro phages as measured by 3H-Thymidine uptake by 
thymocytes stimulated by 1:2 diluted supernatant 
containing the lnterleukin- 1 produced by the 
macrophages and expressed as counts per minute. 
CYCLOSPORINE IL-l (1 :2) 
FUNGIZONE 
Ex # 16.0 
CONCENIRATION (ug/ml) 
8.0 4.0 2.0 1.0 0.0 IN-C 
12 124 109 204 220 152 347 
81.3 81.4 126 211 195 235 
97.6 211 211 200 355 134 
72.0 135 135 130 256 342 
!58 101 181 245 173 269 
64.3 256 287 496 359 260 
13 63.0 112 99.1 178 221 197 222 
67.2 64.1 70.6 117 276 110 151 
66.3 64.7 94.0 109 97.6 166 246 
65.3 75.8 109 100 116 115 106 
85.8 93.3 158 246 124 119 146 
53.9 102 156 187 141 110 212 
49.2 82.7 153 !58 284 240 138 
49.9 80.9 182 285 271 182 122 
Mean 78.4 112 155 206 216 202 168 
S.E. 8.1 14.9 15.1 26.9 23.1 22.1 18.2 
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TABLE 17a . (continued) 
BG 
12 108 41.5 225 115 96.6 104 
54.7 47.5 74.5 74.3 61.8 119 
13 54.5 59.7 52.5 53 .8 87.7 72.8 75.4 
41.4 33.0 33.3 43.4 46.5 65 .6 64.7 
38.5 34.5 28.6 40.3 64.0 69.3 72.8 
34.8 31.7 31.1 46.2 73.3 83.1 100 
Mean 55.3 41.3 74.2 62.2 71.7 85.6 78.2 
S.E . 11.1 4.4 31.0 11.7 7.5 8.7 7.6 
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TABLE 17b. Effect of liposomal amphotericin B on cyclosporine 
compromised macrophages as measured by JH-
Thymidine uptake by thymocytes stimulated by 1:2 
diluted supernatant containing the ln terleukin-1 
produced by the macrophages and expressed as counts 
per minute. 
CYCLOSPORINE IL-l (1:2) 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 325 362 255 181 349 294 
280 314 195 219 172 217 
331 160 211 245 422 170 
264 233 248 322 178 156 
233 273 260 215 208 155 
321 222 197 283 145 292 
13 143 145 131 100 74.2 133 158 
173 201 173 117 154 228 151 
151 222 187 129 179 122 156 
249 186 176 99.3 82.7 254 112 
232 203 187 200 157 165 129 
106 222 230 184 219 232 283 
226 141 135 137 176 162 172 
149 180 219 197 206 161 217 
Mean 227 219 200 188 194 196 172 


















90.2 78.1 Ill 78.9 66.8 
96.8 80.7 79.0 68.8 99.2 
71.3 63.4 66.6 90.6 51.3 86.2 
73.6 57 .9 38.9 59.5 90.2 64.2 
40.7 34.8 56.9 51.1 61.8 63.7 
37.0 44.6 66.1 39.2 74.9 48.0 
68.3 59.9 69.8 64.7 74.0 65.5 
10.1 7.4 9.9 7.6 7.3 7.9 
The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with 1 :2 diluted supernatant 
produced by macrophages from cyclosporine 
compromised splenocytes . 
p-VALUES for CYCLOSPORINE IL-l (1:2) 
(Fungizone and ArnBisome) 
p-value 
Drug 
Drug Dose x 
Dose 
p= 0.000 0.034 0.000 
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TABLE 18a. Effect of amphotericin B on cyclophosphamide 
compromised macrophages as measured by 3H-
Thymidine uptake by thymocytes stimulated by 
undiluted supernatant containing the lnterleukin-1 
produced by the macrophages and expressed as counts 
per minute. 
CYCLOPHOSPHAMIDE IL-l (1:1) 
FUNGIZONE 
Ex # 16.0 
CONCENTRATION (ug/ml) 
8.0 4.0 2.0 1.0 0.0 IN-C 
12 66.6 108 106 89.5 190 191 
42.4 177 106 95.3 139 210 
102 80.2 107 122 253 198 
122 121 128 129 154 197 
231 154 111 105 241 227 
174 151 123 210 238 235 
13 88.3 110 148 307 227 280 210 
113 141 333 265 279 231 240 
73.1 101 185 226 252 162 317 
72.2 119 134 220 188 265 327 
74.6 97.5 180 198 140 264 340 
76.1 94.2 174 148 213 254 179 
53.4 110 115 238 403 207 212 
119 120 150 181 345 309 280 
Mean 101 120 150 181 233 231 263 
S.E. 13.5 7.1 15.9 18.1 20.0 10.7 21.6 
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TABLE 18a. (continued) 
BG 
12 28.4 25.8 34.0 21.0 57.2 56.3 
39.8 23.0 41.3 25 .2 70.0 53.6 
13 46.0 83.6 121 135 100 
42.2 129 145 123 67.4 
40.6 62.6 125 98.6 94.7 
34.9 45.7 65.3 124 136 
Mean 38.7 61.6 88.6 87 .8 99.5 
S.E. 2.5 16.4 19.4 21.0 14.1 
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TABLE 18b. Effect of liposomal amphotericin B on 
cyclophosphamide compromised macrophages as 
measured by 3H-Thymidine uptake by thymocytes 
stimulated by undiluted supernatant containing the 
lnterleukin-1 produced by the macrophages and 
expressed as counts per minute . 
CYCLOPHOSPHAMIDE IL-l (1:1) 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 390 171 137 151 102 74.5 
266 268 233 !51 101 179 
325 356 183 149 162 142 
210 265 256 139 78.7 135 
247 244 199 181 164 139 
227 241 133 200 186 78.6 
13 289 170 107 86.8 123 121 277 
390 212 116 167 122 119 262 
222 178 156 146 128 144 234 
290 167 115 153 123 110 307 
185 282 280 168 153 147 220 
207 220 176 185 208 146 448 
202 220 202 283 193 188 252 
182 195 281 252 202 232 439 
Mean 259 228 184 172 146 140 305 


















123 70.7 44.1 25.2 37 .7 
79.2 60.3 43.9 33.8 50.8 
138 55.0 42 .8 75.8 59.9 96.8 
68.6 15.2 55 .6 53.1 53.5 128 
32.4 43 .5 53.6 41.4 43.6 85 .3 
123 41.9 47 .4 34.5 57.4 94.6 
94.0 47 .8 47.9 44.0 50.5 101.2 
16.6 7.8 2.2 7.4 3.4 9.3 
The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with undiluted supernatant 
produced by macrophages from cyclophosphamide 
compromised splenocytes. 
p-VALUES for CYCLOPHOSPHAMIDE IL-l (1 :1) 
(Fungizone and AmBisome) 
Drug 
p-value Drug Dose x 
Dose 
p = 0.026 0.689 0.000 
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TABLE 19a. Effect of amphoter icin B on cyclophosphamide 
compromised macrophages as measured by 3H-
Thymidine uptake by thymocytes stimulated by 1:2 
diluted supernatant containing the lnterleukin-1 
produced by the macro phages and expressed as counts 
per minute. 
CYCLOPHOSPHAMIDE IL-l (1:2) 
FUNGIZONE 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 93.7 124 182 130 286 152 
78.7 119 148 124 230 114 
181 87.7 146 91.7 98.4 149 
82.7 109 200 84.6 77.7 124 
95.1 73.3 68.6 116 113 96.1 
79.8 144 189 110 140 134 
13 102 201 94.0 251 219 316 188 
108 159 118 260 343 221 185 
72.2 82.0 247 186 182 246 232 
75 .5 85.2 117 145 237 189 274 
83.5 199 184 172 165 128 146 
83.7 141 219 201 208 221 183 
109 102 108 474 196 200 296 
59.2 158 181 267 290 280 237 
Mean 93.2 127 157 187 199 184 218 
S.E. 7.7 11.1 13.7 27.5 20.5 17.8 18.0 
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TABLE 19a. (continued) 
BG 
12 38.8 48.3 53.8 36.3 47.4 74.8 
67.0 37 .0 33.1 57 .8 56.0 67.9 
13 58 .3 54.4 59.9 77.6 194 98.2 64.0 
48.8 49.4 18.6 76.2 83.4 146 61.5 
49.2 47.3 66.2 71.3 60.3 75.8 68.3 
61.7 53.6 54.3 75.5 53.3 75.4 126 
Mean 54.0 48.3 47.7 65.8 82.4 9.7 80.0 
S.E. 4.2 2.6 7.4 6.6 22.9 12.0 15.4 
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TABLE 19b. Effect of liposomal amphotericin B on 
cyclophosphamide compromised macro phages as 
measured by 3H-Thymidine uptake by thymocytes 
stimulated by 1:2 diluted supernatant containing the 
lnterleukin-1 produced by the macrophages and 
expressed as counts per minute . 
CYCLOPHOSPHAMIDE ll..-1 (1 :2) 
AMBISOME 
CONCENTRATION (ug/ml) 
Ex # 16.0 8.0 4.0 2.0 1.0 0.0 IN-C 
12 212 208 230 120 89.6 84.6 
143 144 161 90.9 90.0 128 
114 212 156 121 128 109 
121 128 161 116 123 91.1 
129 148 137 107 145 147 
214 220 125 Ill !51 74.7 
13 199 191 209 200 124 125 132 
245 267 196 114 152 80.6 174 
234 188 117 150 102 133 321 
203 187 153 134 95.4 86.2 152 
191 116 88.6 198 70.9 87.8 269 
259 172 117 123 128 113 210 
190 257 139 136 151 123 95.5 
118 337 108 111 203 95.6 103 
Mean 184 198 150 131 125 106 182 


















44.0 37.3 67 .7 41.9 48.3 







The p-values for the various aspects of the macrophage 
activation studies which were conducted on 
thymocytes stimulated with 1:2 diluted supernatant 
produced by macrophages from cyclophosphamide 
compromised splenocytes. 
p-VALUES for CYCLOPHOSPHAMIDE IL-l (1:2) 
(Fungizone and AmBisome) 
Drug 
p-value Drug Dose x 
Dose 
p = 0.296 0.477 0.000 
